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Background:  Colorectal cancer (CRC) is the second most diagnosed cancer in 
New Zealand, and New Zealand has amongst the highest rates per capita of CRC 
in the world. CRC is a highly heterogeneous disease with varying clinical 
outcomes, morphology and treatment response. Various molecular 
classifications have been previously described with varying degrees of success in 
prognostication and predicting response to treatment, but none has been 
successful in establishing tailored treatments based on molecular profiling. In 
2015, a large international consortium published a new classification system 
based on gene expression data. While this classification system shows 
considerable promise in subtyping CRC, it has yet to be adopted widely. We aim 
to validate this Consensus Molecular Subtype (CMS) classification system using 
CRC stored within the Cancer Society Tissue Bank (CSTB). 
 
Method: More than 300 snap-frozen tumour tissue samples were available from 
the CSTB between 2002 to 2012. RNA was extracted from 20 milligram of tumour 
samples and sequenced using the Illumina HiSeq platform. Raw sequence reads 
were checked and mapped to human reference genome. Gene expression were 
quantified based on the number of reads mapped to particular gene loci. Gene 
Expression profiles from each patient was used as input data to the publicly 
available CRC subtype classifier from the Colorectal Cancer Subtyping 
Consortium (CRCSC) and subclassified into four individual subtypes. The 
clinicopathological, treatment, outcome and 5-year follow-up data were collected 
retrospectively from patient notes.  
 
Results: Of the 306 patients, 19.3% were CMS1, 45.4% were CMS2, 13.1% were 
CMS3 and 5.2% were CMS4. 17% of CRCs were not classifiable.  CMS1 tumours 
were mainly right-sided, node-negative, poorly-differentiated. CMS2 tumours 
iv 
 
were predominantly left-sided tumours found in male patients and were mainly 
Microsatellite stable (MSS). CMS4 tumours were mainly found in younger 
patients with left sided tumours and present at an advanced stage. The five-year 
survival rates for patients with CMS1, CMS2, CMS3 and CMS4 tumours were 
74.6%, 71.2%, 67.5% and 43.8% respectively (P=0.03). There was no significant 
difference in the chemo-response rate between the four subtypes. When 
subtyping of hepatic metastasis was looked at 50% had incongruent 
classification. 75% of these patients received neoadjuvant therapy prior to hepatic 
resection (P = 0.02). 
 
Conclusion: The CMS classification is reproducible on a large scale and showed 
distinct clinical and histological features within each subtype. Further clinical 
studies are required to assess responsiveness of each subtype to adjuvant therapy 
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Colorectal cancer (CRC) is the second most diagnosed cancer in New Zealand 
with over 3000 new cases diagnosed annually[1], and New Zealand has amongst 
the highest rates per capita of colorectal cancer in the world, with a median 
annual age standardised rate per 100,000 for males of 55.2 (range, 50.8–56.2) and 
for females of 44.1 (range, 42.5–45.0) [2, 3]. CRC has been traditionally 
approached as a single disease while in reality it is a highly heterogeneous and 
complex disease. The Tumour, Node, Metastasis (TNM) staging[4] and 
histological grading systems[5] have traditionally been the main tools used for 
staging, classifying and guiding the use of surgery and adjunctive therapy for 
treating CRC. Complete surgical excision of the primary malignancy coupled 
with adjuvant chemotherapy for high risk patients is the only curative option for 
treating CRC[6]. Despite this, survival and relapse rate vary considerably in CRC 
tumours with similar histopathological features[7-10]. To overcome this issue, 
significant efforts have been made to better understand the limitations of TNM 
staging, the underlying genetics of CRC, and the heterogeneity of CRC in order 
to develop novel classification system to prognosticate and to predict the clinical 
behaviour more accurately. 
 
1.2 Traditional TNM staging and World Health Organization (WHO) grading 
Traditionally CRCs were staged and classified by the Dukes, Australian Clinico-
Pathological Staging (ACPS) or the TNM system. Cuthbert Duke first published 
a staging system for rectal cancer in 1932 through the analysis of the depth of 
invasion and presence of locoregional lymph node involvement[11]. This is then 
staged into Dukes’ A, B and C (Table 1). It provided reliable prognostication for 
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CRCs but fails to consider patients who had metastasis or incurable disease. Since 
then multiple modifications were made by the likes of Kirklin, Dockerty, 
Waugh[12] and Astler-Coller[13] (see Appendix). However, these modifications 
prove to be complex and not easily remembered. In 1981 the ACPS system (Table 
2) was proposed at the gastrointestinal congress in Brisbane, Australia[14]. This 
was later validated by the Concord Hospital, Sydney in 1984[14]. The ACPS is 
commonly used in Australia and the key is the addition of stage ‘D’ which 
denotes the presence of distal metastasis or un-resectable, locally advance 
disease. 
The TNM staging system, which is more universally used, was first devised 
between 1943 and 1952 to stage solid tumours based on the extent of the tumour 
(T), lymphatic and nodal involvement (N) and presence of systemic metastasis 
(M)[4]. Since then the Union for International Cancer Control (UICC) and the 
American Joint Committee on Cancer (AJCC) have contributed to its further 
development to maintain global standards for classifying the extent of tumour 
spread. This system provided a more accurate and detailed analysis CRCs. Table 
3 to 6 shows the TNM staging in detail and Table 7 shows the survival differences 
between the different stages in CRC[15].  
CRC can be histologically classified into mucinous adenocarcinoma (If >50% of 
the lesion consist of mucin), Signet-ring cell adenocarcinoma (When >50% of cells 
contain prominent intracytoplasmic mucin), adenosquamous carcinoma, 
medullary adenocarcinoma and undifferentiated adenocarcinoma[5]. 
Histological grading of CRC is based on the percentage of the tumour showing 
gland like structure and is divided into well (> 95% gland like structure present), 
moderate (50-95% gland like structure present) and poorly differentiated (< 50% 




Table 1: Dukes' Classification of Rectal Cancer [11] 
Dukes’  
A Carcinoma limited to the wall of the rectum 
B spread by direct continuity to the extra-rectal tissues but has 
not yet invaded the regional nodes 
C metastases are present in the regional lymph nodes 
 
Table 2: ACPS Staging of CRCs [14] 
ACPS  
A Tumour infiltrates muscularis propria 
B Tumour infiltrates beyond muscularis propria 
C Local nodal involvement 
D Tumour transected or distal metastasis 
 
Table 3: AJCC T-Staging of CRCs [4] 
T staging  
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in-situ. Intraepithelial or invasion of lamina 
propria 
T1 Tumour invades submucosa 
T2 Tumour invade muscularis propria 
T3 Tumour invades through mascularis propria and into 
pericolorectal tissue 
T4a Tumour penetrates to the surface of visceral pritoneum 
T4b Tumour directly invades or is adherent to other organs or 
structures 
 
Table 4: AJCC N-Staging of CRCs [4] 
N Staging  
Nx Regional nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph node 
 1a Metastasis in one regional lymph node 
 1b Metastasis in 2-3 regional lymph node 
 1c Tumour deposit(s) in subserosa, mesentery, non-
peritonealised pericolorectal tissue without regioal lymph 
node involvement 
N2 Metastasis in 4 or more regional lymph node 
 2a Metastasis in 4-6 regional lymph node 
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 2b Metastasis in 7 or more regional lymph node 
 
Table 5: AJCC M-Staging of CRCs [4] 
M staging  
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 1a Metastasis confined to one organ or tissue 
 1b Metastasis more than one organ site or peritoneum 
 
 
Table 6: AJCC Overall TNM Staging for CRCs [4] 
Overall staging    
Stage T N M 
0 Tis N0 M0 
I T1/2 N0 M0 
II A T3 N0 M0 
 B T4a N0 M0 
 C T4b N0 M0 
III A T1/2 N1 M0 
  T1 N2a M0 
 B T3-4a N1 M0 
  T2-3 N2a M0 
  T1/2 N2b M0 
 C T4a N2a M0 
  T3-4a N2b M0 
  T4b N1/2 M0 
IV A Any T Any N M1a 
 B Any T Any N M1b 
 
 
Table 7: SEER Five-Year Survival Based on Different Staging [11] 
 5-year relative survival (%) 
Year of diagnosis Total Males Females 
1975-1977 50.6 50.1 51.1 
1978-1980 52.3 51.3 53.2 
1981-1983 55.2 55.6 54.8 
1984-1986 58.3 58.8 57.8 
1987-1989 60.2 60.7 59.6 
1990-1992 62.0 62.2 61.7 
1993-1995 59.9 60.1 59.6 
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1996-1998 52.2 62.4 62.0 
1999-2002 64.9 65.7 64.2 
2003-2009 65.4 65.9 65.0 
2009 64.8 65.9 65.0 
    
Stage    
All 64.2 64.7 63.8 
localised 91.4 91.7 91.0 
Regional 70.8 70.6 70.9 
Distant 12.3 11.9 12.6 
Unstaged 26.5 31.0 23.1 
 
Although the combination of the histological appearance, grading and the 
staging of CRC have provided a widely-accepted tool for prognostication and 
predictive value, it fails to consider the underlying differences in genetics and, 
molecular signalling pathway and environmental impact. Thus, it serves as a 
poor tool in prognosticating CRC tumours with similar histopathological 
features, grading and stage. Relapse and survival rates vary widely between 
studies[7-10], some having a relapse rate as high as 60% within the first two years 
of resection[16]. Deciding which patients are most at risk of relapse regardless of 
stage of disease and tailoring appropriate treatment is of upmost importance 
rather than relying on traditional therapeutic recommendations[6]. 
  
1.3 CRC genetics, and molecular signalling pathway  
 
Traditionally three molecular pathways have been described that lead to 
phenotypically distinct CRC (Figure 1): chromosomal instability (CIN), 
microsatellite instability (MSI) and CpG island methylator phenotype 
(CIMP)[17].  In 2012 The Cancer Genome Atlas (TCGA) published their genome 
wide analysis of CRC[18]. It showed not only the 32 commonly recurring 
mutations and its prevalence, but more importantly it showed the five-key 
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signalling pathways involved in the tumorigenesis of CRC (WNT, MAPK, PI3K, 
TGF-β and P53 pathways) within the CIN pathway and its prevalence. 
 
 
Figure 1 Genetic model of the adenoma to carcinoma sequence.  
Copyright: © 2012 Frontiers Media SA, Creative Commons Attribution - Non-Commercial (unported, v3.0) License. 
Obtained from [19] 
 
Canonical WNT pathway – Canonical WNT signalling pathway (WNT/β-catenin 
pathway) is a signalling pathway that leads to the accumulation of β-catenin that 
translocates into the nucleus to act as a transcriptional coactivator. This leads to 
subsequent cellular growth and proliferation[20]. In the absence of WNT, β-
catenin is protealysed and degraded by a degradation complex consisting of axin, 
adenomatosis polyposis coli (APC), protein phosphatase 2A (PP2A), glycogen 
synthase kinase 3 (GSK3) and casein kinase 1α (CK1α)[21]. When WNT binds to 
its receptor, frizzled (FZ), It causes destabilisation of the degradation complex 
(dissociation of Axin, APC and GSK3) leading to an accumulation of β-catenin 
and subsequent transcriptional upregulation of genes[22]. Disruption of the 
canonical WNT pathway has been reported in 93% of all CRC and the genes 
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commonly affected in this pathway are APC (70% of all sporadic CRCs), CTNNB1 
(β-catenin gene -  80%)[18, 23, 24]. Other mutations include the SOX9 mutation 
and upregulation of FZ (17%)[18]. 
 
 
Figure 2. Conical WNT signalling pathway 
Copyright: © 2014 Dove Medical Press Limited, Creative Commons Attribution - Non Commercial (unported, v3.0) 
License. Obtained from [25] 
 
MAPK signalling pathway – Mitogen activating protein kinase (MAPK) 
signalling pathway consists of highly conservative family of protein kinases 
which exist in an inactivated form and is responsible for the transduction of 
signal from a surface receptor to the Deoxyribonucleic acid (DNA). The MAPK 
pathway consists mainly of a receptor tyrosine kinase and three subsequent 
protein kinases; MAPK kinase kinase (MAPKKK), MAPK kinase (MAPKK) and 
MAPK. When an extracellular signal such as growth factor binds to its receptor, 
the receptor tyrosine kinase (RTK) gets activated. It subsequently phosphorylates 
and activates downstream MAPKKK (e.g. BRAF, CRAF). MAPKKK then 
phosphorylate and activates MAPKK (e.g. MEK1, MEK2, MEK5) which then 
activates MAPK (e.g. Erk1, Erk2, JNK1). MAPK activates specific MAPK-
activated protein kinases (MAPKAPK) which leads to a series of cellular changes 
19 
 
such as growth, differentiation and development[26]. RAS/MEK/Erk pathway is 
one of the more well-known MAPK signalling pathway. Upon binding of 
extracellular growth factor (e.g. Epidermal Growth Factor, Insulin-like Growth 
Factor, Human Epidermal Growth Factor 2) to its receptor, RTK activates 
intracellular RAS by swapping a GDP for a GTP[27]. Three RAS genes have been 
implicated with tumorigenesis (KRAS, HRAS and NRAS).  The activated RAS 
then activates the first of the three protein kinases, RAF (MAPKKK) through 
phosphorylation. RAF subsequently phosphorylates downstream MEK 
(MAPKK) and Erk (MAPK). When Erk gets activated, it phosphorylates a whole 
series of downstream proteins (MAPKAPK) which leads to the activation of 
transcription factors, thus allowing proliferation and cellular growth to 
occur[28]. This pathway is commonly dysregulated in CRCs with KRAS mutation 
noted in 35%, BRAF mutation in 10% of CRC[18]. Other mutated genes within 
this pathway includes NRAS, ERBB. KRAS, NRAS and BRAF mutations have 
been shown to be mutually exclusive[29, 30]. 
 
  
Figure 3. MAPK signalling pathway 
Copyright: © 2013 MDPI, Basel Switzerland, Creative Commons Attribution - Non-Commercial (unported, v3.0) 




PI3K/ATK/mTOR pathway – This intracellular signalling pathway is important 
in the regulation of the cell cycle. Binding of cell-surface receptor by growth 
factors, e.g. EGF, IGF-1, Insulin, leads to phosphorylation of PI3K, which in turn 
results in downstream phosphorylation of PIP2 and PIP3[32, 33]. This activates 
AKT which ultimately leads to the activation of mTOR[24]. mTOR functions as a 
serine-threonine protein kinase that regulates cell growth, proliferation, motility 
and division[34]. AKT also inhibits the pro-apoptotic protein BCL-2 and 
increases degradation of P53 (see P53/P21/CDK pathway), thus preventing 
apoptosis[24, 35]. This pathway is downregulated and inhibited by PTEN which 
directly inhibits PI3K[24]. Common genetic aberrations affecting this pathway in 
CRC includes the inactivation of PTEN (10%), upregulation of AKT (commonly 
seen in the early stages of CRC) and activating mutation in PI3K[18, 24] 
 
  
Figure 4. PI3K/ATK/mTOR pathway 
Reproduced with permission from Nature Reviews Drug Discovery. Copyright Springer Nature [36].  
 
TGF-β pathway – TGF-β has a myriad of function in vivo, functioning as a 
tumour suppressor, angiogenesis, immunosuppression and regulating cellular 
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proliferation[37, 38].  Almost all human cells produce TGF-β and have receptors 
for it[38]. The receptor is a dimer consisting of two subunits (TβRI and TβRII). 
Upon binding of TGF-β, TβRII is activated causing phosphorylation of TβRI. 
Consequently, this triggers a wide variety of intracellular signalling pathway; 
most important in relation to tumorigenesis is the SMAD signalling pathway[37]. 
Phosphorylation of SMAD 2 and 3 occurs and this binds to SMAD 4 forming a 
complex that translocates into the nucleus. This leads to downstream 
transcription of genes, particularly P15, CDK2, CDK4, cyclin A and Cyclin E, 
leading to cell cycle arrest at the G1 phase[39].  This pathway is dysregulated in 
80% of CRCs leading to dysregulation of proliferation, growth and 
differentiation[18, 24]. Frameshift mutation of the TβRII gene occurs in 85% of 
CRCs, especially with hereditary nonpolyposis colorectal cancer (HNPCC)[40]. 
SMAD4 is mutated in 30% of CRCs[18]. 
 
Figure 5.  TGF-β pathway 




P53/P21/CDK pathway - This pathway ultimately leads to cell cycle arrest in the 
G1/S phase, preventing further cellular growth, proliferation and DNA repair, 
cellular senescence or apoptosis from occurring[42]. The initiation of this 
pathway starts with the activation of the P53 protein via a stress signal. Once p53 
is activated, it binds to DNA and facilitates the transcription of multiple genes 
including hsa-miR34a, p21 and several other downstream genes[42]. hsa-miR34a 
is a tumour suppressor gene and has a pro-apoptotic and senescent properties. It 
has been shown to be strong inhibitors of BCL-2, cyclin D1 and cyclin E2[43]. P21 
binds to CDK complex, thereby inhibiting its action and arresting cell cycle and 
preventing the progression of cells from G1 to S phase. Upon cell cycle arrest, p53 
induces DNA repair, senescence or apoptosis[42]. 
 
These signalling pathways are not mutually exclusive and have complex 
interactions; cross-communication commonly occurs between them. This leads 
to a wide variety of phenotypical presentation of CRC and account for the inter-
tumoral heterogeneity of CRC, which is later discussed. 
 
1.4 Heterogeneity of CRC:  
 
Tumour heterogeneity is collectively caused by intra-tumoral, inter-tumoral 
differences and the complex relationship and interaction of tumours with its their 
microenvironment either pre-operatively or perioperatively[44].  
 
Intra-tumoral differences: Each tumour is made up of a multitude of sub-clonal 
cells, each having distinct biological and molecular properties with varying 
degrees of mutation[44]. In 1976, Peter Norwell described the concept of clonal 
structure and evolution of sub-clones in cancer[45]. He states that the clonal 
relationship among cells arise when selection operates on individual cells to 
induce a survival advantage or disadvantage. It can also emerge because of 
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mutation over time without selection (genetic drift). This has since been reported 
in many epithelial and haematological malignancies. The first study[46] to show 
such clonal “evolution” was from a lobular breast cancer in which the authors 
described a substantial number of sub-dominant somatic mutations becoming 
dominant from the primary tumour to the metastatic population through a 
process known as clonal expansion over a nine-year period. This has been 
replicated in CRC whereby there is discordance of mutation between primary 
and metastatic population as shown in the accumulation of mutation in KRAS, 
BRAF and PIK3CA[44]. Todaro et al[47] consolidated this further by stating that 
CRC starts as a stem cell disease and through clonal evolution, forms sub clones 
of cancer stem cells that confer survival benefit and chemo-resistance which 
subsequently leads to recurrence or distal metastasis.  The presence of these 
different sub-clones within each tumour and selection processes leads to the 
differences in the clinical behaviour, metastatic potential and drug-resistance in 
phenotypical and histologically similar tumours. 
 
Inter-tumoural differences: Inter-tumoral differences is the difference between 
tumours within a diagnostic group such as CRC. Different signalling and 
molecular pathways are involved in the tumorigenesis of CRCs. Traditionally 
three molecular pathways have been described that lead to phenotypically 
distinct CRC: chromosomal instability (CIN), microsatellite instability (MSI) and 
CpG island methylator phenotype (CIMP)[17]. They can occur in combination or 
can be mutually exclusive, generating inter-tumoural heterogeneity [17, 44]. CIN 
describes the accumulation of a multitude of mutations in the oncogenes and 
tumour suppressor genes[44]. It has been commonly conceptualised as the step 
wise accumulation of mutation particularly the APC, KRAS, DCC and P53 
gene[17, 48-50]. It is known that the total accumulation rather than the sequence 
of mutation and allelic loss that is responsible for tumorigenesis and the tumours 
biological behaviour[17].  In 1989 Fearon and Volgestein [49] showed that there 
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was a median of four to five allelic deletion in individual chromosomes in 
colorectal carcinomas and that patients with greater number of losses had a 
considerably worse prognosis despite having tumours of similar grade, size and 
stage.  
The CIMP pathway on the other hand follows an entirely different molecular 
pathway, involving the hyper-methylation of CpG islands within promoter 
regions which leads to epigenetic silencing of genes, most commonly the MLH1 
gene. These sporadic tumours differ considerably in that they are usually 
associated with the BRAF V600E mutation and clinically develop from sessile 
serrated adenoma[17]. They are typically poorly-differentiated, right sided 
malignancies with good overall prognosis[17].  
The MSI pathway involves CRCs that arise through the dysfunction of the DNA 
mismatch repair genes (dMMR genes)[51]. These typically involves the MLH1, 
MSH2, MS6 and PMS2 gene[52]. These gene products are involved in the 
recognition and repair of mismatches that occur during DNA replication. A 
defect in this process allows genetic errors and mutations to occur, thereby 
facilitating the CRC tumorigenesis. These tumours are termed MSI due to the 
deletion or insertion of repetitive short segments of DNA (also known as 
microsatellites)[53]. Phenotypically, these tumours are right sided, mucinous, 
early staged, less likely to metastasise and are typically seen in young or female 
patients[53]. 
 
Host and microenvironment: This is a commonly overlooked source of 
heterogeneity within CRCs. The phenotypical presentation of CRC can be 
influenced by a multitude of host and micro-environmental factors [44, 54-58]. 
The tumour micro-environment is a dynamic network involving the hypoxic 
microenvironment, tumour cells, stromal matrix, extracellular matrix (ECM), 
lymphocytes, tumour associated macrophage (TAM), fibroblast and other cells. 
These have an important role in the initiation, growth, propagation and 
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metastatic ability of tumour cells. The hypoxic microenvironment within tumour 
triggers a whole host of metabolic adaptation, favouring growth and propagation 
of tumour population adapted to the environment. An example of this is via 
activation of pyruvate kinase isoform M1 and M2 (PKM1/2). Under hypoxic 
situations, tumours with the tetramer, PKM2, proliferate faster than those with 
PKM1[54], switching to an anaerobic metabolism to confer a survival benefit; this 
involves rapid generation of adenosine triphosphate (ATP), biosynthesis of 
macromolecule and maintenance of appropriate redox state to minimise damage 
from reactive oxygen species[55]. The hypoxic state also facilitates epithelial-
mesenchymal transition (EMT), a key step towards metastasis[55]; hypoxia 
induces epigenetic modification that represses epithelial genes and activate 
mesenchymal genes. One such example is the HDAC3[56]. 
 
Tumour behaviour and histological staging are closely related to the host 
immune response profile [44, 58]. Immune cells secrete a whole host of cytokines 
and growth factors that can be either anti-tumoural or pro-neoplastic. The 
location, quantity and quality of immune cells seen within the tumour also 
predicts differences with the clinical outcomes[44]. High densities of CD8+, CD45 
T cells, TH1 are associated with tumours of earlier stage (I and II) and better 
prognosis[58]. Whereas TH17 cells are associated with more advance stage and 
poor prognosis[58]. The same can be said about M2 macrophage, with high levels 
associated with poor prognosis and high metastatic rates[44]. How these immune 
contextures are formed and how they evolve throughout the disease process is 
yet to be fully understood[44]. 
In addition to this, recent studies into colonic microbiota [59, 60], dietary fibre 
intake [61], Vitamin C and D [62-64], and sedentary lifestyle [65] have all been 




In summary, the heterogeneity sub clonal population, genetic allelic loss pattern, 
different signalling and molecular pathway and the “second hit” by 
environmental and host factors leads to development of genetically and 
phenotypically distinct tumours with different clinical behaviour and response 
to treatment. Hence the traditional method of grading and classifying them per 
histopathological feature is not only crude, but also, it does not take into 
consideration the molecular behaviour of each individual tumour. Novel 
molecular based classification systems are thus required to facilitate precision 
oncological treatment. 
 
1.5 Novel classifications systems: 
 
First attempts at reclassifying CRCs molecularly were done by dividing them 
based on their MSI, CIN and CIMP status. As previously discussed, these 
tumours have distinct histological, molecular, phenotypical and clinical 
differences. Classification of these cancers could be made based on relatively 
simpler investigations, negating the need for expensive tests such as microarray 
analysis or high throughput next generation sequencing (NGS). MSI can be 
diagnosed using NCI consensus panel, analysing five microsatellite markers 
which includes D2S123, D5S346, D17S250, BAT25 and BAT26[66]. However due 
to financial constraints, immunohistochemistry (IHC) has been used instead to 
assess the presence or absence of mismatch repair gene proteins[53]. CIMP can 
be quantitatively assessed using MethyLight technology®[66]. Many centres 
have utilised BRAF testing as a surrogate marker for CIMP instead.  Refinement 
to classification based around these markers ultimately led to a classification 
proposed by Jass et al[67], in which they classify CRCs into 5 types; Type1 being 
CIMP-high (CIMP-H), Microsatellite instable-high (MSI-H) and BRAF mutation, 
Type 2 being CIMP-H, microsatellite stable (MSS) with BRAF mutation, Type 3 
being CIMP-low (CIMP-L), Microsatellite stable (MSS) with KRAS mutation, 
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Type 4 being CIN and Type 5 being CIMP-negative and MSI-H. This has led to 
significant changes in the management of patients with CRCs particularly in 
terms of screening and follow-up[53].  
The downside of this classification is that testing for dMMR and MSI is done 
based on patients who clinically fulfilled the Amsterdam II[68] and revised 
Bethesda Criteria[69] (See appendix). There are concerns that significant 
proportions of the patients with MSI, particularly Asian populations, may not be 
tested as these criteria were based on a western population[70, 71]. Neither IHC 
nor MSI panel testing has 100% accuracy[53]. With regards to IHC, the biggest 
barrier to accuracy and interpretation of the test is with regards to uniformity of 
tissue fixation with formalin, which can lead to patchiness, reduced staining or 
in some cases complete loss of staining[53]. This classification only identifies 15% 
of sporadic tumours as MSI tumours[53]. It does not address the differences and 
heterogeneity in CIN tumours which comprise 85% of all sporadic CRCs. More 
importantly for clinicians, this classification does not offer a clear prognostication 
between the five subtypes.  
 
To overcome these issues and building on the current knowledge of the 
molecular genetics of CRCs, novel strategies such as microarray analysis[72] and 
high throughput genomic analysis[73-80] have been used to analyse gene 
expression profiles and classify CRC into molecularly and genetically distinct 
groups to help better predict, prognosticate and aid the treatment of CRC. 
 
Microarray analysis: 
Microarray analysis uses a collection of RNA/DNA probes to analyse and 
quantify a set of pre-chosen target RNAs. It provides a rapid, easy to use and 
comparatively less labour-intensive way of analysing and profiling CRCs 
compared to high throughput genomic analysis. Currently only two 
commercially available, FDA approved CRC microarray analysis exist – the 18 
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gene Coloprint® and the 12 gene Oncotype DX®. While these tests have been 
externally validated in multiple studies [72, 81-83], only the prognostic value of 
these tests have been validated. Using multivariate analysis, Maak et al showed 
that Coloprint® was the only independent variable to prognosticate survival and 
recurrence for stage II CRC[81].  It remains to be seen whether patients offered 
these tests have improved outcomes over those who are not offered these tests. 
Microarray analysis also suffers from inherent design bias and are only as good 
as the genes selected for analysis. It lacks the ability to analyse and quantify the 
entire transcriptome. 
 
High-throughput genomic analysis: 
High-throughput genomic analysis or NGS, has made great strides since its 
introduction more than a decade ago[84]. With cost reduction and improved 
sequencing, it allows researchers the ability to carry out a more detailed analysis 
of the transcriptome and interrogate the entire transcriptome without any prior 
knowledge of it, thereby eliminating any potential design bias[84].  Ever since 
TCGA published their genomics analysis of CRC, multiple investigators have 
attempted to use NGS to reclassify CRCs based on their molecular-genetics. 
Below is a summary of the six most relevant large-scale studies on this. 
 
Budiska et al[75] 
Using unsupervised clustering and NGS, 1113 CRCs were classified into five 
different gene expression subtypes: surface crypt-like, lower crypt-like, CIMP-H-
like, mesenchymal and mixed.  CIMP-H-like had similar properties to what was 
described by the TCGA as being hypermutated tumour (BRAF, MSI CIMP-H) 
with better recurrence free survival (RFS) but poor survival after relapse (SAR). 
Tumours described as mesenchymal tumours also displayed lower overall 
survival (OS) and early relapse and was also found to have high levels of 
epithelial-mesenchymal transition (EMT) related gene expression and resulting 
29 
 
in high rates of distant metastasis. Crypt-like tumours on the other hand had 
better OS. No distinct histological pattern was observed in any one subtype. 
 
Marisa et al.[76] 
In this study, the authors sub-classified CRCs into six subtypes (C1-C6) through 
the analysis of transcriptomic data of 566 CRCs.  C2,3 and 4 were more frequently 
CIMP-H, showed highest rate of EMT gene expression and tended to be proximal 
tumours with serrated phenotype. C4 subtype had the poorest OS and RFS. C1,5 
and 6 on the other hand were more frequently CIN, CIMP-negative, TP53 
negative and were clinically more distal.  
 
Roepman et al.[77] 
By using unsupervised clustering of whole transcriptome data of 188 CRCs, three 
major groups were identified in this study. This was then further validated with 
543 stage II to III CRC tumours. Type A (MMR deficient epithelial subtype) was 
associated with BRAF or KRAS mutation, had a higher rate of gene mutation and 
had a high proportion of MSI. Clinically it was associated with right-sided 
tumours, female gender, poor differentiation and generally good OS. Type B 
(proliferative epithelial subtype) was almost exclusively MSS, showed a low rate 
of gene mutations and had a high rate of chemo-responsiveness. Type C 
(mesenchymal subtype) showed high frequency of mesenchymal markers and 
clinically was associated with the poorest OS with exceptionally poor response 
to chemotherapy. 
 
De Sousa e Melo et al[78] 
Again, using unsupervised clustering of whole transcriptome data of 90 CRCs, 
CRCs was divided into three key groups: CIN, MSI and CIMP-H. This was then 
validated with more than 1100 tumours. The first two subgroups have been well 
described. The third group was CIMP-H but MSS. These tumours had serrated 
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phenotypes and high levels of EMT gene expression. They also had poorer OS 
and were resistant to epidermal growth factor receptor (EGFR)-targeted therapy. 
 
Sadanadam et al.[79] 
This study included 1290 CRCs and divided them into five different subtypes: 
stem-like, inflammatory, transit-amplifying, goblet like and enterocyte. The first 
three subtypes, particularly the stem-like group displayed high EMT expression 
and had particularly poor OS. The latter two had better disease-free survival 
(DFS) and the authors suggested that these patients may be spared chemotherapy 
when the tumours were early staged and localised. 
 
Schickler et al.[80] 
After validating publicly available datasets involving 1643 tumours, CRCs were 
classified into two main groups (type 1 and 2) in this study, which were later 
further sub classified into five subgroups. Type 1 generally had poor OS and was 
characterised by high EMT gene expression. This group had a mixture of MSI-H 
and MSS CRC, whereas Type 2 CRCs were mainly MSS, with epithelial 
phenotype and good OS. 
 
There are multiple similarities and differences between the six classification 
systems mentioned above. Most of the similarities are related to MSI and EMT 
tumours (Table 8). The lack of concordance between these classifications could 
potentially be explained by differences in the cohorts, data processing, genomic 
analysis technique and clustering algorithms used[85]. Thus, there has been a 
poor uptake of these techniques universally.  There is a need for a more universal 
classification that is easily and reliably replicable. In 2015, a large international 
consortium set about addressing this issue and proposed the consensus 




Table 8: Similarities Between the Six Studies 
 CRC subtype 
 Common feature 
Classification 
publication 
MSI  EMT enriched 
Budishka et al. CIMP-H-like Mesenchymal 
Merisa et al. C2,3 C4 
Roepman et al. Type A Type C 
De Sousa e Melo et al Type 2 Type 3 
Sadanadam et al Inflammatory Stem like 
Schickler et al Type 1 Type 1 
 
1.6 Consensus Molecular Subtypes of CRC:  
 
Due to the differences found between the different classification methods 
previously described[75-80], the CRC Subtyping consortium (CRCSC) was 
formed to identify any potential core subtyping patterns. Data were pooled from 
18 different databases including the TCGA database. 27 nodes were then 
generated using 6 different classification systems[75-80].  Using an integrating 
network-based approach and unsupervised cluster algorithm (Markov Cluster 
Algorithm), recurring patterns were then identified, and CRCs were reclassified 
based on these recurring patterns. These are described as CMS 1-4[85].   
 
CMS1: These tumours are typically hyper-mutated, hyper-methylated with low 
somatic copy number alterations (SCNA). The majority of CMS1 tumours are 
MSI-H and have defects in the dMMR gene. BRAF was frequently mutated in this 
group. Receptor tyrosine kinase (RTK) and mitogen-activated protein kinase 
(MAPK) pathways were the most commonly activated signalling pathway. 
Histopathologically they were associated with a high level of TH1 and cytotoxic 
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T cell infiltration, and commonly had higher histopathological grade. Clinically 
they were frequently diagnosed in females with right-sided tumours. Despite 
having a relatively good OS, patients were found to have a poorer SAR. 
 
CMS2: This subgroup contained mainly CIN tumours with high SCNA. They had 
higher levels of oncogene activation and losses of tumour suppressor gene 
compared to other CIN tumours. Both WNT and MYC signalling pathways were 
commonly activated. Clinically, these were mainly left-sided tumours and 
usually of a more advance stage (III, IV). Despite this, these patients had the best 
OS compared to the other three subtypes. 
 
CMS3: Tumours in this subgroup were also CIN. However, their SCNA count 
were lower when compared to CMS2 and 4. They were commonly right-sided 
tumours. KRAS mutation were commonly seen. Overexpression of genes and 
proteins to increase glycolysis and lactate production was found in this subtype; 
as a consequence of this, these tumours have prominent metabolic adaptation. 
 
CMS 4: This subgroup contained CIN tumours with histological mesenchymal 
features. EMT related genes were commonly activated. In addition, this 
subgroup of CRC also showed gene expression profiles that associated with 
stromal infiltration and overexpression of extracellular matrix protein. Clinically 
these tumours are often advanced stage and commonly metastasize. Patients 
with these tumours tend to have a poorer OS and RFS. 
 
When individual mutations were looked at, no individual event or genetic 
mutation was limited to a specific subtype. The same can be said about signal 
transduction cascade and pathways. This emphasizes the poor genotype to 
phenotype correlation in CRCs. It also illustrates the importance that 
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classification of CRCs should not be based solely on singular validated 
biomarkers or on histological features.  
 
Having said that, there are issues with CMS system worth considering. A recent 
publication by Dunne et al [86] showed that intra-tumoural differences can 
undermine the accuracy of CMS. They found different regions within the tumour 
itself, e.g. invasive front, tumour core and lymph node metastasis, harbour 
distinctively different gene expression. They also shown that individual CRC can 
potentially be misclassified as CMS4 if tissue for analysis was taken from the 
invasive front. Recent evidence suggests that the presence of EMT-associated 
genes seen in CMS4 may reflect upregulated genes from fibroblast and 
mesenchymal cells present in the background rather than directly from the 
tumour itself[55, 72, 87, 88]. This together with improvements in techniques 
involved in nucleic extraction and purification, may lead to less CMS4 or the 




Though the CMS classification system shows immense promise in the subtyping 
of CRC and may allow for subsequent tailored precision-based treatment, it 
needs to be externally validated with large-scale studies. We in Christchurch are 
in an excellent position to validate this molecular subtyping system, having 
access to over 500 CRC tissue samples from the Cancer Society Tissue Bank 
(CSTB), complete with clinical and outcome data for these patients. We aim to 
evaluate the demography and clinical outcomes of our patient cohort (Chapter 
2), validate the clinical behaviour of each individual subtypes (Chapter 3), 
validate the prognosis and survival outcomes of each individual subtypes 
(Chapter 4), evaluate the response of individual subtypes to adjuvant therapy 
(Chapter 5), and finally assess the subtypes of distant metastasis (Chapter 6). It is 
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hoped that by externally validating the CMS classification, it will allow for future 
prospective studies on the predictive utility of this system in guiding adjunctive 








Aim:  To perform an epidemiological study on colorectal cancers (CRC) collected 
in our tissue bank and to identify any potential risk factors affecting recurrence 
and survival outcome. 
 
Method: Clinical data was retrospectively collected on all CRC patients who had 
their tissue stored in the Cancer Society Tissue Bank (CSTB) between 2002 to 
2012. Only patients with sporadic, non-hereditary tumours were included. Chi-
square and Mann-Whitney test were performed to identify associations between 
variables. Univariate and multivariate binary logistic regression was used to 
assess correlation and identify potential risk factor. 
 
Results: 480 patients met inclusion criteria with a median age of 74.3 and an equal 
male to female distribution. CRCs were predominantly right-sided (47.5%). 
Rectal tumours only accounted for 15.6%. Right-sided tumours had a higher 
female prevalence (64.8% P<0.01), locally advanced (59.1%) and had features of 
microsatellite instability (MSI). The overall five-year survival was 63.7% with 
colonic adenocarcinoma having a significantly better five-year survival 
compared to rectal adenocarcinoma (66% versus 51.9%). The five-year survival 
rates for stage I-IV disease were 77%, 74.3%, 52.6% and 20% respectively.  Only 
node positivity, metastatic disease at time of surgery, local recurrence and 
subsequent development of metastasis were risk factors for poorer survival on 
multivariate analysis (Odds Ratio of 4.28, 7.69, 16.91 and 28.72 respectively). No 




Conclusion: The epidemiology and survival outcomes for the current cohort are 
comparable to published results worldwide.  No clinical or histological variables 
other than advanced disease and recurrence were reliably predictive of adverse 
outcomes. Additional methods such as molecular classification may help further 





Adenocarcinoma of the colon and rectum is a highly heterogeneous disease and 
its incidence is on the rise globally. It has been reported in 2012 that globally 1.36 
million were diagnosed with colorectal cancer. It is the second most commonly 
diagnosed cancer in New Zealand[2]. New Zealand has the highest incidence of 
CRC as previously mention in section 1.1. With the current classification and 
treatment options available, reported survival and recurrences vary significantly 
within the literature. The Consensus Molecular Subtyping (CMS) classification 
sets about reclassifying CRC based on their molecular genetics using next 
generation sequencing (NGS) technology. Before external validation of this 
system can be undertaken, it is important to understand the characteristics of the 




The aims of this study were to identify 
• The demographics of the patients with CRCs 
• The clinical and histological characteristics associated with recurrence and 
survival of patients with CRCs 
• potential clinical or histological features that may be used to prognosticate 




This study was performed as part of a study looking into the external validation 
of the CMS classification. A retrospective audit was carried out on all CRCs 
stored within the CSTB between January 2002 and December 2014. Patients were 
consented for CRCs to be stored in the CSTB prior to surgery. The specifics on 
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how the CRC tissues were stored and RNA extracted will be discussed in more 
detail in Chapter 3. Inclusion criteria for this study included all patients with 
treatment naïve colorectal cancer above the age of 18, with complete clinical data 
set. Patients who had prior CRCs, metachronous or synchronous CRCs, 
hereditary tumours, or neoadjuvant chemotherapy or radiotherapy were 
excluded from the study (Figure 6). The inclusion and exclusion criteria were set 
as such to allow accurate interpretation of molecular-genetics and its clinical 
behaviour when external validation of the CMS classification gets underway.  
Demographic information, post-operative staging, subsequent recurrence, 
metastasis and histological data were retrospectively collected from patient notes 
or electronic notes and entered into a custom-built Microsoft Access (Microsoft, 
Redmond, Washington, USA) database.  
For analysis of association, Chi-square test was used for binary data and t-Test 
for continuous data. Both univariate and multivariate analysis were performed 
using Cox regression to assess if any clinical or histological variables could 
account for the recurrence and survival of patients. Kaplan-Meier survival curves 
were used to assess survival outcomes between groups. These were performed 





Over the thirteen-year period, a total of 563 patients with treatment-naïve 
colorectal cancer were identified from the CSTB. After inclusion and exclusion 
criteria were applied, 480 met criteria and were subsequently analysed (Figure 
6). A total of eighty-three patients were excluded. Sixty-one patients were 
excluded as they had either synchronous, metachronous tumours. Eleven 
patients were excluded as they had adenomas as oppose to adenocarcinomas. A 





The overall demographics of the patients and the histological features of the 
CRCs are displayed in Table 9. The median age of presentation was 74.3 years 
with a range of 28.7 to 94 years. Patients were mainly ethnically European, 
constituting 97% of the cohort. There was an equal male to female distribution 
(48.8% vs 51.2% respectively). Right sided tumours were the most predominant 
at 47.5%. A similar pattern seen when the cohort was broken down into 
individual age groups; right sided tumours were the most predominant tumours 
in all age groups (Figure 8). Due to the inclusion criteria, only 15.6% of CRCs 
were rectal cancers. There were significantly more right sided tumours in females 
while the opposite could be said for the male cohorts (Table 10). Right sided 
tumours had a significantly higher proportion poorly-differentiation, and 
mucinous subtype. 
 
Figure 6 - Flow chart depicting the inclusion and exclusion of patients within this 
study. CSTB - Cancer Society Tissue Bank 
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Table 9: Demographics of Patients with CRCs 
Total Sporadic Singular Cancer = 480 
   
 
Total T1 T2  T3 T4 
n 480 17 87 287 89 
Age  74.3 72 74.2 74.3 74.4 





Male 234 10 41 135 48 
Female 246 7 46 152 41 
Ethnicity 
     
European  465 17 84 275 89 
Asian  4 0 0 4 0 
Maori  11 0 3 8 0 
Colon  405 15 65 242 83 
Right  228 4 32 155 37 
Left  177 11 33 87 46 
Rectum  75 2 22 45 6 
Poorly-
Differentiated  
100 1 12 59 28 
Mucinous  55 1 8 35 11 
Signet Cell  4 0 1 3 0 
LVI 166 1 15 95 55 
PNI 61 0 1 35 25 
EVI 70 0 0 39 31 
Node Negative 292 13 69 177 33 
Node Positive 188 4 18 110 56 
Distant Metastasis 30 0 0 15 15 
TNM Stage 1  82 13 69 0 0 
TNM Stage 2  203 0 0 173 30 
TNM Stage 3  165 4 18 99 44 
TNM Stage 4  30 0 0 15 15 
Patients who had 
adjuvant treatment  
129 2 10 81 36 
Node negative    25 0 0 16 7 
Node positive 104 2 8 65 29 
Subsequent 
metastasis 
81 2 6 47 26 
Median Time (days) 437 (34 - 
1981)  
521 (409 








Local Recurrence 16 1 0 9 6 
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Figure 8. Distribution of CRC based on age groups 
 
 
Table 10: Comparison of Right and Left Sided CRCs 
 Right Left OR P Value 
Female   59.1% 42.6% 1.95 <0.01 
T>2  84.1% 77.7% 1.51 0.08 
N +ve  39.3% 38.1% 0.93 0.79 
M+ve  6.0% 7.9% 0.73 0.41 
Poor Differentiation  30.2% 13.4% 2.79 <0.01 
Mucinous  17.5% 8.4% 2.30 <0.01 
Lymphovascular 
Invasion 
37.7% 34.7% 1.14 0.50 
Perineural Invasion  11.9% 15.3% 0.74 0.29 
Extramural venous 
invasion  
12.3% 20.3% 0.55 0.02 
Isolated Extramural 
Deposit  
7.9% 7.4% 1.08 0.84 
Local Recurrence 2.8% 4.5% 0.61 0.34 
Subsequent 
metastasis  
14.7% 16.8% 0.85 0.53 
MSI – Microsatellite instability. N +ve – Node positive. M +ve – Distant metastasis present on diagnosis. Red denotes 
significant difference between right and left sided CRCs 
 
 

















There were significant lower survival rates, higher rates of N staging, M staging, 
subsequent development of metastasis and histological variables, such as poorly 
differentiated, lympho-vascular invasion (LVI), perineural invasion (PNI) and 
isolated extramural tumour deposit as the T staging progressively increased. As 
shown in Table 11, there is an increasing association with these negative clinical 
variables when the invasion of tumour extends deeper. 
 
Table 11: Clinical and Histological Outcomes of CRCs Based on T-Staging 
T staging 1 2 3 4 P-Value 
Gender 58.8% 47.1% 47.0% 53.9% 0.56 
N+ve 23.5% 20.7% 38.3% 62.9% <0.01 
Stage IV 
Disease 




11.8% 6.9% 16.4% 29.2% <0.01 
Poorly 
Differentiated 
5.9% 13.8% 20.6% 31.5% 0.01 
LVI 5.9% 17.4% 33.1% 62.5% <0.01 
PNI 0.0% 1.1% 12.2% 28.4% <0.01 
EVI 0.0% 0.0% 13.6% 35.2% <0.01 
IED 0.4% 3.4% 5.6% 15.7% <0.01 
Died from 
Disease 
11.8% 6.9% 15.7% 33.3% <0.01 
N+ve – Node positive disease; LVI – Lymphovascular involvement; PNI – Perineural invasion; EVI – Extramural venous 
involvement; IED – Isolated extramural deposit; 
 
Patients with clinical features such as male, rectal cancers, nodal positivity, local 
recurrence, distal metastasis, and histological features, such as poor 
differentiation, LVI, PNI, extramural venous involvement were associated with 
higher rates of mortality due to CRC (Table 12). Patients who were male, 
diagnosed with rectal cancers, node positivity, metastasis at time of surgery, poor 
differentiation, LVI, PNI, extramural venous involvement, isolated extramural 
deposits and subsequent local recurrence were also found to have significantly 
higher rates of subsequent distal metastasis with odd’s ratio (OR) of 2.28, 2.34, 
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7.42, 10.41, 1.99, 3.33, 5.72, 6.05, 6.13 and 16.6 respectively.  No such association 
were found with local recurrence. 
 
Table 12: Mortality and Recurrences Based on Patient Demographics and Histological Patterns 
Odd’s ratio, CI and P-value 
 Death from disease Distant metastasis Local Recurrence 
Male vs 
Female 
2.25 1.37-3.67 P<0.01 2.28 1.38-3.75 P=0.01 1.78 0.64-4.99 P=0.26 
Age Group N/A N/A P=0.34 N/A N/A P=0.17 N/A N/A P=0.23 
Rectum vs 
colon 
2.34 1.33-4.13 P<0.01 1.88 1.04-3.37 P=0.02 2.56 0.86-7.59 P=0.08 
Right vs 
Left 




1.99 1.17-3.38 P=0.01 1.93 1.13-3.29 P=0.01 0.87 0.24-3.13 P=0.83 
Mucinous  0.98 0.44-1.98 P=0.85 0.82 0.37-1.81 P=0.65 1.83 0.50-6.63 P=0.35 
Signet cell  1.61 0.16-15.6 P=0.68 1.65 0.17-16.1 P=0.66   P=0.71 
LVI 3.33 2.03-5.43 P<0.01 3.34 2.04-5.47 P<0.01 1.13 0.4-3.17 P=0.80 
PNI 5.72 3.21-10.2 P<0.01 7.12 3.98-12.8 P<0.01 0.98 0.22-4.41 P=0.98 
EVI 6.05 3.47-10.5 P<0.01 6.33 3.63-11.1 P<0.01 1.36 0.38-4.91 P=0.62 
IED 6.13 2.95-12.7 P<0.01 4.81 2.31-10.0 P<0.01 1.96 0.43-9.18 P=0.37 
N+ve 7.42 4.26-12.9 P<0.01 4.86 2.89-8.18 P<0.01 2.68 0.96-7.5 P=0.05 
Stage IV 10.41 4.73-22.9 P<0.00
1 
2.67 1.2-5.94 P<0.01 1 0.13-7.83 P=0.99 
LR 16.6 5.21-52.9 P<0.00
1 





P<0.01    5.36 1.95-
14.73 
P<0.01 
MSI 0.21 0.03-1.57 P=0.09 0.21 0.09-1.61 0.1 0.34 0.18-2.64 P=0.36 
N+ve – Node positive disease; LVI – Lymphovascular involvement; PNI – Perineural invasion; EVI – Extramural venous 
involvement; IED – Isolated extramural deposit; LR – Local recurrance; MSI – Microsatellite instability. 
 
 
2.5.2 Analysis of correlation 
 
Univariate and multivariate analysis were used to predict survival or recurrence 
based on clinical features and histological findings. When univariate analysis 
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was performed, most clinical variable and histological variable seem to be a risk 
factor for cancer specific mortality (Table 13). However, when multivariate 
analysis was performed, only patients who were node positive, with metastatic 
disease at time of surgery, local recurrence or subsequent distal metastasis had a 
significantly higher risk of dying from the disease, with a OR of 4.28, 7.69, 16.91 
and 28.72 respectively (Table 13). As for the risk of developing subsequent 
metastasis, the multivariate analysis showed that male patients, rectal tumours, 
nodal involvement, local recurrence, and perineural involvement were variables 
that were predictive of developing subsequent metastasis (OR of 1.98, 2.29, 2.11, 
4.41 and 4.4 respectively). patients who developed subsequent metastasis was the 
only risk factor identified for developing local recurrence with an OR of 5.43 
(Table 15). 
 
Table 13: Univariate and Multivariate analysis for Cancer Specific mortality 
Survival Univariate Analysis Multivariate analysis 
 OR 95% CI P Value OR 95% CI P Value 
Gender (Male) 2.25 1.37-3.64 <0.01 1.29 0.49-3.38 0.61 
Age Group   0.34   0.44 
Site (Rectum) 2.34 1.33-4.13 <0.01 1.87 0.57-6.17 0.31 
Side (Right) 0.9 0.52-1.56 0.71 0.76 0.24-2.41 0.65 
T staging   <0.01   0.67 





M staging 10.4 4.74-
22.92 






















0.69 0.25 0-209233 0.81 
Mucinous 
Tumour 
0.93 0.43-1.98 0.85 0.68 0.14-7.99 0.63 
Lymphovascular 
Invasion 

















<0.01 1.09 0.41-6.12 0.90 
 
 
Table 14: Univariate and Multivariate Analysis for Subsequent Metastasis 
Metastases Univariate Analysis Multivariate analysis 
 OR 95% CI P Value OR 95% CI P Value 
Gender (Male) 2.28 1.38-3.75 <0.01 1.98 1.09-3.55 0.02 
Age Group   0.17   0.12 
Site (Rectum) 1.88 1.04-3.37 0.03 2.29 1.09-4.86 0.03 
Side (Right) 0.86 0.50-1.49 0.59 1.00 0.51-2.00 0.98 
T Staging   <0.01   0.73 
N staging 4.86 2.89-8.18 <0.01 2.11 1.10-4.03 0.03 




















0.82 0.37-1.81 0.62 0.79 0.27-2.35 0.79 
Lymphovascular 
Invasion 















<0.01 2.36 0.81-6.83 0.59 
 
Table 15: Univariate and Multivariate Analysis for Local Recurrence 
Local 
recurrance 
Univariate Analysis Multivariate analysis 
 OR 95% CI P Value OR 95% CI P Value 
Gender (M) 1.78 0.64-4.99 0.27 1.27 0.43-3.73 0.66 
Age Group   0.27    
Site (rectum) 2.56 0.86-7.59 0.09 1.82 0.53-6.23 0.34 
Side (Right) 0.64 0.19-2.13 0.47 0.54 0.14-2.10 0.37 
T staging   0.51    
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N staging 2.68 0.96-7.50 0.06 1.88 0.56-6.26 0.31 










0.87 0.24-3.12 0.84 0.99 0.26-3.89 0.99 
Signet ring 0.99 N/A 0.99 <0.01 N/A 0.99 
Mucinous 1.83 0.50-6.63 0.36 2.35 0.59-9.26 0.22 
LVI 1.13 0.40-3.17 0.81 0.99 0.26-3.80 0.99 








1.99 0.43-9.18 0.38 1.43 0.23-8.84 0.69 




The overall five-year survival within this cohort was 63.7%. Patients with colonic 
adenocarcinoma had a significantly higher five-year survival when compared to 
rectal adenocarcinoma of 66% versus 51.9% (Figure 9). The five-year overall 
survival according to T staging were 79% for T1, 74.3% for T2, 66.1% for T3 and 
42.9% for T4. Whereas the five-year overall survival according to overall staging 
was 77%, 74.3%, 52.6% and 20% for stage I, II, III and IV respectively. These 
differences were statistically significant with a P-value of less than 0.05. When 
patients were stratified into three different age group (Group 1, <50; Group 2, 50-
79; Group 3, >80), the five-year overall survival were significantly better for 




























2.6 Discussion  
 
The demographics and survival outcomes of this study cohort are similar to what 
has been reported in the literature[15, 89]. CRC within this study was 
predominantly a disease of the older age group. However as with what is being 
observed in the literature, the incidence of CRC in patients who are less than 50 
years is on the rise[90-94], and this trend is also reflected within this cohort, with 
9 out of 11 patients who are less than 50 years of age, treated after 2008. CRC were 
predominantly right sided disease, and this is particularly true for female 
patients. Right sided tumours were more likely to be locally advanced and poorly 
differentiated. This is reflected in multiple studies[95-98]. Two meta-analyses [99, 
100] have recently shown that right sided tumours have a different clinic-
pathological presentation and have a significantly worse prognosis and higher 
risk of death when compared to left sided tumours. This adds to the ever-
increasing clinical evidence that right sided tumours are of a separate entity [95, 
98, 101, 102].  Studies have shown that right-sided tumours have different 
molecular-genetic makeup; lower expression of c-myc[103] and TP53[104] and a 
higher incidence of MSI[105]. Recent NGS and unsupervised clustering have 
shown that right-sided tumours are more commonly seen in some subtypes of 
CRCs[75, 78, 85]. However, the clinical outcome of these tumours was not hugely 
affected, with similar local recurrence and survival outcomes as shown by the 
multivariate analysis performed within this study.   By merely classifying 
tumours to left and right-sided is an over-simplistic alternative and as a result, 
the prognosis and survival outcomes of reported epidemiological studies vary 
significantly[99]. 
 
Looking at survival, results are comparable to other Australasian and North 
American results[15, 89, 106, 107]. When compared with the SEER database, the 
five-year survival for local and regional disease were similar, however the five-
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year survival for patients with metastatic disease within this study was higher 
(20% versus 16%).  Survival was marginally better when different age groups 
were compared; 72.7% versus 65% for young patients. 
 
More importantly this study showed that N staging, M staging and disease 
recurrence were the only significant risk factors for dying from CRC. This adds 
to the ever-increasing contradictory evidence within the available literature 
regarding which clinicopathological variables are predictive for survival. Ponz 
de leon et al [108] and Park et al [109] suggested that only morphological 
variables are the only important variables that are predictive of survival, 
however Nissan et al [110] suggested by their multivariate analysis that 
pathological variables such as LVI, and tumour grading are predictive of survival 
outcome. This contradiction highlights the difficulty of predicting patient 
outcome base on the traditional clinic-pathological classification system. The 
difference in cohort demographic, geographical and environmental variation and 
underlying heterogeneity in genetics accounts for this vast difference in outcome. 
Hence there needs to be a more robust, universal classification which accounts 
the molecular genetic differences in CRC, to better predict and prognosticate 
CRCs. 
 
There are inherent biases to this study. This study was part of a larger study to 
externally validate the CMS classification system, as such, certain exclusion 
criteria such as neoadjuvant therapy, hereditary tumours and synchronous 
tumours were not avoidable. Large proportions of stage IV CRCs and emergency 
resections were excluded from the cohort as these tumours were either not 
operated on or the resection occurred at a time not conducive for immediate 
freezing and storing of specimens. This together with the inclusion and exclusion 
criteria set at the beginning of the study meant that a substantial proportion and 
important segment of the population with CRCs including large proportions of 
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patients with rectal cancers have been excluded, ultimately effecting the 
prognosis and outcome of the study. Small numbers in both emergency 
resections and stage IV disease may artificially improve outcomes as reflected in 
the five-year survival rates shown within this study. The other major limitation 
of this study is the retrospective nature of this study. Though the tissue stored 
within CSTB were prospectively stored, the clinical data collected in this study 
was retrospectively collected. The accuracy of the collected data is dependant 
accuracy of the record keeping and pathological reporting, particularly between 
2002 to 2006 where T staging and histological reporting was not standardized. 
 
Despite this, this study does provide an adequate insight to the clinical behaviour 
of our CRC population; more importantly it does high light the short comings of 
traditional classification system and the limited ability of traditional histological 





In conclusion, the demographic and survival outcome shown is comparable to 
results from other developed countries. The TNM system is good at 
prognosticating survival. Additional methods such as molecular classification 
may help further in prognostication.  
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3. External Validation of Consensus Molecular Subtypes of 
CRC - Demography and Histopathological Features 




Aim: To externally validate the Consensus Molecular Subtyping (CMS) of 
colorectal cancer (CRC) and to identify clinical and histological associations 
within each subtype. 
 
Methods: 306 patients were selected from the 480 patients (discussed in chapter 
2). Frozen tissues divided, and RNA extracted. Sample preparation, including 
library creation and ribosomal RNA depletion was carried out using Illumina 
TruSeq V2 reagents (NZGL, Massey University, Palmerston North). RNA 
sequencing carried out using Illumina HiSeq 2500 V4 platform. Raw sequence 
reads were checked and mapped to human reference genome. Gene expression 
profiles from each patient were used as input data to the publicly available CRC 
subtype classifier[85]. The clinicopathological, treatment outcome and 5-year 
follow-up data were collected retrospectively from patient notes.  
 
Results:  Of the 306 patients, 19.3% were CMS1, 45.4% were CMS2, 13.1% were 
CMS3 and 5.2% were CMS4. 17% of CRCs were not classifiable.  CMS1 tumours 
were mainly right-sided, node-negative, poorly-differentiated and Microsatellite 
instable (MSI) tumours with a high proportion of mucinous histology. CMS2 
tumours were predominantly left-sided tumours found in male patients and 
were mainly Microsatellite stable (MSS). CMS4 tumours were mainly found in 
younger patients with left sided tumours and present at an advanced stage. This 
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compares well to what was published by the Colorectal Cancer Subtyping 
Consortium (CRCSC)[85]. 
 
Conclusion: This study showed that the CMS classification is reproducible on a 
large scale and showed robust and distinct clinical and histological features 
within each subtype. More effort is required to investigate the relative absence of 





The cost associated with next generation sequencing (NGS) have decreased 
significantly and with it an increased uptake in genome wide analysis of CRCs. 
This has led to a flurry of new molecular classification of CRCs[67, 73-80, 85]. The 
most promising of which is the CMS classification published by the CRC 
Subtyping consortium (CRCSC)[85], who pooled data from 18 international 
databases. Four molecularly and genetically distinct subtypes with distinct 
phenotypes and clinical behaviour were described. If reproducible, it is hoped 
that it allows further risk stratification and prognostication of CRCs, enabling 
decisive clinical management, particularly in patients with stage II and III 
disease. Multiple studies have been conducted to evaluate the robustness and 
reproducibility of this classification [87, 111-116].  Building on the work 
performed by Purcell et al[87], we aim to externally validate the accuracy of the 
CMS classification, and in this chapter, focus on the clinical and histological 




3.3.1 Patient selection 
 
Some 306 patients were selected from the previously described 480 patients 
(Chapter 2). Due to funding restrictions, the initial recruitment target of 500 
patients was reduced to 300. As a result, recruitment was focused heavily on 
patients that were less than fifty years of age and greater than eighty years of age.  
All patients that were excluded from the 480-patient cohort were patients aged 




3.3.2 Nucleic acid extraction, sequencing and classification 
 
Patients were consented for CRCs to be stored in the Cancer Society Tissue Bank 
(CSTB) prior to surgery. Tumour tissue was flash frozen with liquid nitrogen 
after resection and stored at a temperature of -80° Celsius. Selected tissue was 
then transferred to RNAlater ICE (Qiagen N.V. Germany) and stored at a 
temperature of -20° Celsius. Twenty milligrams of frozen tumour tissue was 
divided, RNA extracted using RNeasy® kit (Qiagen N.V. Germany). 
Quantification of purified nucleic acid performed using NanoDrop 2000c 
spectrophotometer (Thermo Scientific, Asheville, NC, USA). Sample preparation, 
including library creation and ribosomal RNA depletion was carried out by using 
Illumina TruSeq V2 reagents. RNA sequencing carried out using Illumina HiSeq 
2500 V4 platform. Raw sequence reads were quality controlled and mapped to 
human reference genome. Gene expression was quantified based on the number 
of reads mapped to particular gene loci. Gene expression profiles from each 
patient were used as input data to the publicly available CRC subtype classifier 
(v1.0.0, https://www.synapse.org/#!Synapse:syn4961785)[85] and classified into 4 
subtypes.  
 
3.3.3 Clinical data collection 
 
The clinicopathological, treatment outcome and five-year follow-up data were 
collected retrospectively from patient notes. Tumours located proximal to the 
splenic flexure were documented as right sided tumour, tumours located distal 
to the splenic flexure and proximal to the rectosigmoid junction were 
documented as left sided tumour and tumours located distal and including 
rectosigmoid junction were documented as rectal tumours. In terms of 
histological findings, tumours that contained more than 50% mucin were 
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documented as mucinous tumours while tumours containing more than 50% 
signet cells were documented as signet cell tumour. 
 
3.3.4 Data analysis 
 
Data was entered into and entered into a custom-built Microsoft Access 
(Microsoft, Redmond, Washington, USA) database. Statistical analysis using Chi-
square was carried out for categorical data and Kruskal-Wallis test used for 
continuous data. These were performed using SPSS® version 20 (IBM Corp®). A 
P-Value of <0.05 was deemed significant. 
 
3.3.5 Ethics approval 
 
The study protocol was approved by the University of Otago Human Ethics 




Of the 306 patients included in the analysis, 47.1% (144) were male and 52.9% 
(162) were female. The median age was 73.9 (range 29-92) years of age. 3.9% (12) 
of patients were aged 50 or less and 28.8% were aged 80 or more. 96.4% (295) 
were Caucasian, 2.9% (9) were Maori and 0.7% (2) were of Asian descent. In terms 
of the distribution of the tumours, 44.1% (135) were right sided, 37.9% (116) were 
left sided and 18% (55) were rectal tumours. 17.3% (53) of patients had stage I 
disease, 41.2% (126) had stage II disease, 34.3% (105) had Stage III disease and 
7.2% (22) had stage IV disease. Histologically 17.3% (53) were poorly-
differentiated and 10.5% (32) were mucinous. Table 16 shows the demographics 




Table 16: Demographics and Characteristics of patients 
   
n Percentage 
Demography Gender Male 144 47.1   
Female 162 52.9  
Age Median 73.9 
 
  
≤50 12 3.9   
51-79 206 67.3   
80 88 28.8  
Ethnicity European 295 96.4   
Maori 9 2.9   
Asian 2 0.7 
Staging and 
Histology 
Site Right 135 44.1 
  
Left 116 37.9   
Rectum 55 18  
Stage I 53 17.3   
II 126 41.2   
III 105 34.3   
IV 22 7.2  
Poorly differentiated 53 17.3  
Mucinous 32 10.5  
Signet cell 2 0.7  
Lymphovascular invasion 100 32.7 
 
Extramural venous invasion 45 14.7  
Isolated extramural deposit 24 7.8  
Perineural invasion 37 12.1 
 
 
19.3% (59) patients were classified as CMS1, 45.4% (139) as CMS2, 13.1% (40) as 
CMS3 and 5.2% (16) as CMS4. 17% (52) of all patients were not classifiable. Table 
17 represents the distribution of patients according to the four subtypes and how 
it compares to the CRCSC[85]. 
 
 
Table 17:  Proportion of Consensus Subtypes within our study and CRCSC 
 
Total CMS1 CMS2 CMS3 CMS4 Unclassifiable 
Our 
Study 
306 19.3% 45.4% 13.1% 5.2% 17.0% 
Guinney 
et al  








Table 18: Demographics and Characteristics of patients that were classifiable in this study and from the CRCSC 
CRCSC data obtained from Guinney et al[85], Supplementary table 5. 
 
 
As shown on Table 18, other than having proportionately more females, more 
stage I disease and less stage III disease, the demography, clinical and 
pathological characteristics of this cohort is largely similar to that of the CRCSC. 
By comparing the clinicopathological feature between each consensus subtypes 
(see Appendix Table 31), CMS1 tumours were significantly associated with 
female gender (OR 2.95, P <0.01), right-sided tumours (OR 2.42, P<0.01), node-
negative disease (OR 1.75 P=0.01), poorly-differentiated (OR 4.78, P<0.01), 
mucinous tumour (OR 3.57, P<0.01) and a higher proportion of MSI tumours (OR 
9.9, P<0.01). These patients were also less likely to receive adjuvant treatment (OR 
1.76, P=0.03). CMS2 tumours were significantly associated with male patients 
(OR1.61, P<0.01), left-sided tumour (OR 1.92, P<0.01) and MSS tumours (OR 1.15, 
P<0.01). There were no significant clinicopathological characteristics associated 
with CMS3 other than the fact that these were associated with larger tumours 
and higher T-staging (P<0.01). CMS4 was associated with left-sided tumours (OR 
2.42, P=0.05) and advanced overall staging (P=0.03). Aside from CMS4 tumours 





Percentage n Percentage  
Gender Male 118 46.4 1536 54 0.02  
Female 136 53.5 1308 46 0.02 
Age Median 73.9 
 
66   
Site Right 111 43.7 1034 39 0.16  
Left 95 37.4 1219 46 0.06  
Rectum 48 18.9 398 15 0.10 
Stage I 48 18.9 354 12 <0.01  
II 109 42.9 1151 39 0.22  
III 81 31.8 1210 41 <0.01  
IV 16 6.3 236 8 0.39 
Poorly 
differentiated 
49 19.3 88 16 0.27 
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having a higher proportion of isolated extramural deposits, there were no 
significant difference in any other histological features between the four 
subtypes. There was no significant difference in the local recurrence rates and 
subsequent distant metastasis between the four subtypes. Table 19 summarises 
the clinicopathological features of each consensus subtypes found in our study 
and that of the CRCSC. 
 
Table 19: Summary of clinicopathological findings associated with individual subtypes and comparing with the 
CRCSC[78] 







CMS1 older Female Right 
sided 
 High grade 
tumour 
 MSI 
CMS2 younger Male Left 
sided 
 Not Poorly 
Differentiated 
 MSS 
CMS2  Male Left 
sided 
 Lower grade 
tumour 
  
CMS3     Advanced T-
staging 
  
CMS3   Right 
sided 
    


















 High grade 
tumour 
 MSS 





The key findings within this study were that CMS1 tumours occurred mainly in 
females and were mainly right-sided and poorly-differentiated; CMS2 tumours 
were mainly found in younger, male patients and were less likely to be poorly-
differentiated; CMS4 were mainly left-sided tumours associated with advanced 
staged malignancies.  This matches the findings reported by the CRCSC[85] and 
61 
 
by multiple other studies[87, 90-94, 111-116]. This study represents one of the 
larger studies to externally validate the Consensus Molecular Subtypes by 
utilizing RNA-derived sequencing data. 
 
There were proportionately more tumours classified as CMS1 and 2 and only 
5.2% of tumours classified as CMS4. There were also more tumours that were 
unclassifiable at 17% compared to 13% as published by the CRCSC[85]. The 
reason for a higher proportion of CMS1 and CMS2 tumours and comparatively 
less CMS4 tumours could partly be due to the recruitment process. Due to 
funding restrictions, there was only sufficient funds to process approximately 300 
patients as oppose to the initial plan of 500 patients. As such recruitment was 
focused mainly on patients that were 50 years or less and 80 years or more. The 
rationale for this came from recent publications which cited the increasing 
incidence of CRCs in the very young and old patients[117, 118]. With higher 
proportions of younger and older patients, it is not surprising that there was a 
higher proportion of CMS1 and CMS2 tumour as these tumours are associated 
with older and younger patients respectively. The other possible explanation 
could be due to the slight differences in methodology the cohort. As explained 
by Purcell et al[87], the CRCSC utilised TCGA data which has since been 
updated. They also utilised data from micro-array derived datasets which is 
different to the current study, which is strictly RNA-sequencing derived. Thus, 
potentially leading to a difference in the classification of the tumours. 
 
With regards to the smaller numbers of CMS4 tumours in this study (5.2% as 
oppose to 23%), recent evidence suggest that the presence of EMT-associated 
genes seen in CMS4 tumours may reflect upregulated genes derived from 
fibroblast and mesenchymal cells present in the stromal background rather than 
directly from the tumour itself[55, 72, 87, 88]. This together with improvements 
in techniques involved in nucleic extraction and purification, may lead to less 
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tumours being classified as CMS4 tumour or the complete absence of it. This 
would clearly limit the clinical applicability of the CMS classification as a whole. 
 
The second reason for the smaller number of CMS4 tumour is due to the fact that 
patients that had neoadjuvant therapy were excluded. Trumpi et al[112] 
concluded in their study that neoadjuvant therapy induces a mesenchymal 
phenotype in residue tumour cells and as such may lead to an increase in CMS4 
subtypes. With exclusions of neoadjuvant treatment, one would thus expect a 
reduction in the number of CMS4 tumours. This effect will be explored in more 
detail in Chapter 6. 
 
This study showed that the clinical and histo-pathological characteristics of 
patients with tumours that were classifiable into the four CMS subtypes were 
largely similar to that of the CRCSC[85]. The only difference was that in this 
study there was a higher female ratio, a higher rate of stage I disease and a lower 
rate of stage III disease. One could thus argue that with this slight difference in 
population, how could this study be used to externally validate the CMS 
classification. It is important to recognise that the population of both studies 
should be matched prior to classification and not after. The information on 
patients with non-classifiable tumours from the CRCSC is not publicly available 
for analysis. Thus, making it difficult to ensure that the clinical and 
histopathological characteristics of patients in both cohorts are comparable prior 
to classification.  
 
Despite this, this study has successfully shown that individual CMS subtypes 
have distinct clinical features and reiterates the heterogenous nature of CRCs, re-
enforcing the fact that traditional phenotype-based classifications are inaccurate 
and do not have the ability to prognostic and predict the behaviours of CRCs. 
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None of the CMS tumours had significant association with any histological 
features. MSI-H tumours are present in both CMS1 and CMS3 tumours.  
 
 
3.6 Conclusion  
 
In conclusion, by using RNA-derived sequencing data, successful validation of 
the Consensus Molecular Subtyping for CRCs was performed, and distinct 
clinical features associated with each subtype was reproduced. There is 
increasing evidence that disputes the presence of CMS4 tumours and more 
research into this field is required.  
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Aim: To identify the prognosis and survival outcomes of the different Consensus 
Molecular Subtypes (CMS). 
 
Methods: 306 patients were selected. Frozen tissue was divided, and RNA 
extracted. Sample preparation, including library creation and ribosomal RNA 
depletion was carried out using Illumina TruSeq V2 reagents (NZGL, Massey 
University, Palmerston North). RNA sequencing carried out using Illumina 
HiSeq 2500 V4 platform. Raw sequence reads were checked and mapped to a 
human reference genome. Gene expression profiles from each patient were used 
as input data to the publicly available CRC subtype classifier[85]. The follow-up 
data including five-year survival and recurrence were collected retrospectively 
from patient notes.  
 
Results: The five-year survival rates for patients with CMS1, CMS2, CMS3 and 
CMS4 tumours were 67.6%, 68%, 55.5% and 41.1% respectively (P=0.03). Forty-
five patients developed relapse. The local recurrence rates for CMS1, CMS2, 
CMS3 and CMS4 tumours were 3.9%, 3.6%, 7.5% and 0% respectively (P=0.55). 
The distant metastatic rates were 11.9%, 20.1%, 12.5% and 31.2% for CMS1, 
CMS2, CMS3 and CMS4 tumours respectively (P=0.47). The median survival after 
relapse (SAR) was 15.3 months, 15.1 months, 25.4 months and 4.72 months for 




Conclusion: The five-year overall survival rates were similar to those published 
by the Colorectal Subtyping Consortium (CRCSC)[85]. However, the TNM 
staging system is better than the CMS classification for predicting survival 
outcomes. This study was too small to make any meaningful assessments on the 





The ability to accurately prognosticate and predict the clinical behaviour of 
colorectal cancers (CRCs) is the holy grail in the management of CRCs, 
particularly with regards to recurrence and survival.  For many years clinicians 
have relied on clinico-pathological based classifications system, such as Dukes’ 
and TNM, to help prognosticate and predict treatment outcome for patients 
suffering from CRCs. Multiple studies have shown the inadequacy and 
inaccuracies associated with such classifications[7-10]. The Consensus Molecular 
Subtyping for CRCs have been shown to be a robust and promising way of 
prognosticating CRCs[85]. In this chapter, we aim to replicate and validate the 
ability of CMS classification in prognosticating CRCs, particularly the survival 
and recurrence rates of each subtype. 
 
4.3 Methods  
 
The same 306 patients described in Chapter 3 were included.  The process of 
nucleic acid extraction, sequencing and classification into the four subtypes has 
been described in detail in Chapter 3. Follow-up data, including survival, 
recurrence and distant metastasis were collected retrospectively from patient 
notes. Data was then entered into a custom-built Microsoft Access database 
(Microsoft, Redmond, Washington, USA). Statistical analysis using Kaplan-
Meier survival was used to analyse five-year survival and recurrence rates. Cox 
regression analysis was used to assess potential independent prognostic factors 
associated with survival. These were performed using SPSS® version 20 (IBM 






As described in Chapter 3, of the 306 patients included in the study, fifty-two 
tumours (17%) were unclassifiable. Of the remaining 254 tumours, fifty-nine 
(19.3%) were classified as CMS1, 139 (45.4%) were classified as CMS2, forty 
(13.1%) were classified as CMS3 and sixteen (5.2%) were classified as CMS4. The 
median follow-up period was fifty months (0.2 to 174 months). The five-year 
survival for patients with CMS1, CMS2, CMS3 and CMS4 tumours were 67.6%, 
68%, 55.5% and 41.1% respectively (P=0.03). When the five-year survival of 
individual subtypes was compared against each other, only patients with CMS4 
tumours had a significantly worse overall survival with a median survival of 
forty-five months (P<0.05). The five-year disease-free survival (DSF) was 67.6%, 









Figure 14: Five-Year Disease-Free Survival of The Four Consensus Molecular Subtypes. 
 
Of the 306 patients, forty-five patients had relapse of their disease; nine had local 
recurrence and forty-two developed distant metastasis within the five-year 
follow up period. There was no significant difference in the median survival after 
relapse (SAR) which was 15.3 months, 15.1 months, 25.4 months and 4.72 months 




Figure 15: Five-year Survival After Relapse of each CMS Subtypes 
 
Table 20: Univariate and multivariate Analysis for survival outcomes 
Survival Univariate Analysis Multivariate analysis 
 OR 95% CI P Value OR 95% CI P Value 
Gender (Male) 1.93 1.12-3.33 0.18 1.15 0.55-2.31 0.71 
Site (Rectum) 2.65 1.39-5.07 <0.01 1.37 0.62-3.03 0.44 
CMS (CMS4) 2.55 1.32-6.50 0.04 1.94 0.59-6.35 0.27 
T staging (T4) 3.73 1.95-7.31 <0.01 1.67 0.74-3.78 0.22 
N staging 5.10 2.55-
10.18 
<0.01 2.37 1.02-5.48 0.04 
M staging 6.92 3.37-
14.23 
<0.01 2.36 1.82-6.81 0.02 
Local 
Recurrence 

















1.43 0.32-1.53 0.97 1.25 0.28-1.97 0.81 
Mucinous 
Tumour 
0.44 0.11-1.82 0.25 0.72 0.14-5.43 0.46 
Lymphovascular 
Invasion 
2.54 1.37-4.71 <0.01 0.86 0.34-2.67 0.74 
Perineural 
Invasion 
3.86 1.93-7.72 <0.01 0.95 0.41-6.12 0.93 
Extra-mural 
venous invasion 
2.80 1.40-5.60 <0.01 0.44 0.12-1.64 0.22 
Isolated extra-
mural deposit 






Results in red signifies prognostic markers in both univariate and multivariate analysis. 
 
Table 20 shows the results of the Cox regression analysis. In the multivariate 
analysis, only subsequent metastasis, N and M staging were identified as 
independent factors associated with poorer survival outcome. Subsequent 
metastasis, N and M staging had an Odds’ ratio of 15.72, 2.37 and 2.36 
respectively (P<0.05). 
 
Table 21: The Local Recurrence and Metastasis in Different Subtypes During the Whole Study Period 
    All 
samples 


































There was no significant difference in the number of local recurrences or distant 
metastases between each of the CMS subtypes during the follow up period (Table 
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21). The local recurrence rate for CMS1, CMS2, CMS3, CMS4 tumours was 3.9%, 
3.6%, 7.5% and 0% respectively (P=0.55). The median time to local recurrence was 
53.5, 24.7 and 21.6 months respectively. The distant metastatic rate was 11.9%, 
20.1%, 12.5% and 31.2% for CMS1, CMS2, CMS3 and CMS4 respectively (P=0.20) 




The overall survival shown in this study was similar to the CRCSC[85]. Patients 
with CMS4 tumours had significantly worse five-year overall survival of 41.1% 
(P=0.03). This was slightly lower compared to the five-year overall survival rate 
of 62% reported by the CRCSC[85]. A similar trend was observed in the five-year 
DFS when compared to the results from the CRCSC. CMS1 by far had the highest 
disease-free survival (75% from the CRCSC versus 67.6% from this cohort). When 
SAR was looked at, no significant differences between the four subtypes were 
found. CMS4 had the worse outcome with a median of 4.72 months. CMS1, and 
CMS2 showed similar median SAR at roughly 15 months. This is dramatically 
different to what was reported by the CRCSC. They reported that CMS1 had by 
far the lowest SAR of nine months followed by CMS4 of twenty-four months[85]. 
This difference could be explained by the small number of patients who 
developed recurrence in the current cohort and the substantial number of 
censored patients, which was 18%. This represents the biggest limitation of this 
study. By recruiting a larger number of patients and particularly the ones with 
recurrence, it is expected the results will mirror that of the CRCSC. The same 
could be said about the rate of local recurrence and rate of distant metastasis. 
Only nine and forty-two patients either developed local recurrence or distant 
metastasis. Though not significant, patients with CMS4 tumours had by far the 
highest number of distant metastasis and patients with CMS1 tumours had the 
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lowest number of recurrence and distant metastasis. This could explain why 
CMS1 has such a good prognosis and CMS4 has such a poor one. 
 
This study and multiple other studies[75-80, 85, 119] have shown that patients 
with CMS1 tumours have an excellent overall survival despite having poor 
histological features. This good prognosis could be due to the immune activation 
pathways associated with microsatellite instable (MSI) tumours[119]. The stroma 
of the tumour is highly immunogenic[85, 119, 120] and express prominent levels 
of lymphoid and myeloid-specific genes. It is this that leads to an increase in anti-
tumour immune response associated with CMS1 tumour, thereby keeping the 
growth and spread of the tumour in check.   
 
Despite having a favourable prognosis, CMS1 tumours have one of the poorest 
rates of survival after recurrence[85, 121]. The explanation for this is two-fold. 
Firstly, and from an immunological prospective, advanced MSI tumours develop 
a phenomenon known as the adaptive resistance[122]; These tumours obtain the 
ability to evade host immune responses.  In a normal setting, regulatory T-cells  
function as immune modulators and suppress the inflammatory response to 
allow for self-tolerance[122].  These regulatory T-cells have been found within 
the stroma of MSI tumours and are at especially elevated levels in advanced MSI 
tumours [123-125]. This together with the upregulation of immune evasion 
mechanisms such as the inhibitory checkpoint molecule PD-1 ligand (PD-
L1)[116], causes a down regulation of the anti-tumour response. Thus, allowing 
tumour growth, metastasis and subsequent poor prognosis. Secondly from a 
clinical prospective, metastatic MSI CRCs tend to present as a more advanced, 
unresectable state[126] and are less chemo-responsive particularly to 5-
flourouracil (5-FU) based therapy[51, 127-129]. This together with evidence to 
suggest of subtype switching to CMS4 tumours in hepatic metastasis (discussed 
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in Chapter 6) may explain the lower resectability rates and subsequent poorer 
prognosis in patients with metastatic or recurrent CMS1 tumours.  
 
CMS4 tumours on the other hand has the poorest overall survival, SAR and a 
high rate of subsequent metastasis. Overall five-year survival was only 41.1% and 
median SAR was only 4.72 months. This is due to the fact that CMS4 tumours are 
associated with enrichment of epithelial-mesenchymal transition (EMT) 
associated genes and have increased TGF-β activation and angiogenesis[85, 119]. 
The stroma of these tumours consists of a microenvironment rich in innate 
immune cells and fibroblasts[119, 130]. These carcinoma-associated fibroblasts 
produce a wide array of factors including proangiogenic factors and immune 
suppressive factors[116]. This suppresses the antitumoral effect provided by the 
innate T-lymphocytes.  Furthermore, there is emerging evidence to suggest a 
subtype switching in hepatic metastasis[112] particularly switching from CMS2 
tumours to CMS4 tumours, further reinforcing the aggressive nature of this 
subtype.  
 
Multiple studies have shown the prognosticating ability of the CMS system[85, 
88], however this study represents the first study comparing the prognosticating 
ability of the CMS classification against the traditional TNM system. The key 
difference in survival seen was mainly between CMS4 and the other CMS groups 
(Figure 13, 14). The prognosticating ability of CMS classification still does not 
outperform the traditional TNM staging system. As seen in the multivariate 
analysis (Table 20), only N, M status and subsequent metastasis were significant 
predictors for reduced survival outcomes. CMS was not a significant predictor 
for survival outcome. This limits the translation of this classification system into 
clinical practice. This could firstly be due to the small numbers of CMS4 tumours 
within this study. Having only 16 patients classified as having CMS4 tumours 
meant that the numbers were too low to show significant correlation with 
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mortality. However more importantly, as discussed in Chapter 3, is the validity 
of CMS4 tumour itself. Multiple studies have shown that the enrichment of the 
EMT-associated genes derives primarily from carcinoma-associated fibroblasts 
and its surrounding stroma[55, 72, 87, 88, 113] rather than tumour cells and as 
such puts the validity of CMS4 tumours into question. Li, Arnadottir and Dunne 
et al have all suggested that the location and number of tumour biopsies and the 
underlying intra-tumoural differences can undermine the accuracy of CMS[86, 
113, 131]. With RNA extracted from a single 20mg sample of the tumour and 
without the ability to know whether the stroma of the tumour or the tumour itself 
is being sampled, the accuracy of CMS classification would be significantly 
affected. Multiple biopsies and analysis of the tumour itself might improve the 
accuracy of the classification. With the accuracy of the CMS classification and the 
validity of CMS4 tumours in doubt, it is hardly surprising that CMS4 tumour was 
not found to be an independent factor for survival. 
 
 
4.6 Conclusion  
 
In conclusion, this study has successfully shown distinct survival patterns of each 
individual CMS subtypes. However, the TNM staging system is better than the 
CMS classification for predicting survival outcomes.  Larger numbers of patients 
with recurrent disease are required to validate the metastatic rates and the SAR 
for each subtype.  
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Aim: To evaluate the response and outcome of the different Consensus Molecular 
Subtypes (CMS) of colorectal carcinoma (CRC) to adjuvant therapy. 
 
Methods: 306 patients were selected. Frozen tissue was divided, and RNA 
extracted. Sample preparation, including library creation and ribosomal RNA 
depletion was carried out using Illumina TruSeq V2 reagents (NZGL, Massey 
University, Palmerston North). RNA sequencing was carried out using the 
Illumina HiSeq 2500 V4 platform. Raw sequence reads were checked and 
mapped to human reference genome. Gene expression profiles from each patient 
used as input data to the publicly available CRC subtype classifier[85]. The 5-
year follow-up data including survival and recurrence were collected 
retrospectively from patient notes. Computed Tomography (CT) Scans were 
retrospectively reviewed for tumour load and response to adjuvant therapy.  
 
Results: Eighty out of 254 patients (26.1%) received adjuvant treatment, of which 
twenty-six (10.2%) received palliative therapy. Fourteen patients received 
palliative chemotherapy only and four patients received palliative radiotherapy 
only. There was no significant difference in the chemo-response rate between the 
four subtypes. CMS4 tumours had the poorest chemo-response with all patients 
being poor responders. CMS3 had the best response with 33.3% of its patients 
having a good response to chemotherapy. There was no significant difference in 
the DFS of patients who received adjuvant chemotherapy and those that who did 
not, however there was a trend towards a lower DFS in patients with stage II 




Conclusion: Given the relatively small study, no significant differences in the 
response to adjuvant therapy between the different Consensus Molecular 
Subtypes was noted. Patients with Stage II CMS1 tumour seem to have a reduced 
survival outcome when given adjuvant chemotherapy. TNM staging system 
remains the classification system of choice in terms of determining adjuvant 






 CRCs are highly complex and heterogeneous disease. Deciding when to utilise 
adjuvant therapy and predicting response to adjuvant therapy has proven to be 
difficult. Traditionally, the decision to utilise adjuvant treatment has been based 
on TNM staging and high-risk histological features[6]. Other than microsatellite 
unstable (MSI) tumours showing distinctively poor chemo-responses to FOLFOX 
therapy (5-fluorouracil, leucovarin, oxaloplatin) [127-129], there are very limited 
tools to help clinicians predict the chemo-response of CRCs. Consensus 
Molecular Subtyping offers a promising tool to assist clinicians in the 
management of patients with stage II to IV disease. To better understand this, the 
aim of this chapter is to evaluate the response of individual CMS subtypes to 
adjuvant and palliative therapy.  
 
5.3 Methods  
 
This study was divided into two parts. The first part of the study was to compare 
the responsiveness of each CMS subtypes to palliative chemotherapy. The aim 
was to directly assess the response of individual CMS tumours towards 
chemotherapy and radiotherapy with disease in situ. The second part of the 
study was to assess the effectiveness of adjuvant treatment in the management 
of each CMS subtypes by comparing the rate of local recurrence, distant 
metastasis and survival outcomes post adjuvant treatment. 
5.3.1 Patient selection 
 
The same 306 patients described in Chapter 3 were included. From this cohort, 
patients who received adjuvant treatment, palliative chemotherapy or 




5.3.2 Nucleic acid extraction, sequencing and classification 
 
The process of nucleic acid extraction, sequencing and classification into the four 
subtypes have been described in detail in Chapter 3.  
 
5.3.3 Clinical data collection and analysis: 
 
Five-year follow-up data of selected patients were collected retrospectively from 
patient notes. For the first part of the study, the size, location and distribution of 
the distant metastasis or local recurrence were measured on the CT scan at time 
of relapse. Post palliative treatment CT scans are routinely performed by 
oncologist to assess response to treatment. The size, distribution and location of 
the disease on CT scan was remeasured by the same person. The formal CT report 
was also taken into consideration. A reduction of tumour load by greater than 
50% denotes good response, a stable appearance or a reduction of less than 50% 
denotes a poor response and progression of disease on CT scan while on 
palliative chemotherapy denotes non-responders.  
 
For the second part of the study, data on local recurrence, subsequent metastasis 
and survival outcomes were collected for patients who underwent adjuvant 
chemotherapy or radiotherapy. 
 
Data was then entered into a custom-built Microsoft Access database (Microsoft, 
Redmond, Washington, USA). Statistical analysis using Chi-Square analysis and 
Kaplan-Meier survival analysis to assess differences in treatment response 
between groups. These were performed using SPSS® version 20 (IBM Corp®). A 






As described in Chapter 3, of the 306 patients included in the study, fifty-two 
tumours (17%) were unclassifiable. Of the remaining 254 patients, fifty-nine 
(19.3%) tumours were classified as CMS1, 139 (45.4%) were classified as CMS2, 
forty (13.1%) were classified as CMS3 and sixteen (5.2%) were classified as CMS4.  
During a median follow-up of fifty months (0.2 to 174 months), eighty patients 
(31.5%) received adjuvant treatment; seventy-five patients had adjuvant 
chemotherapy and seventeen patients had adjuvant radiotherapy. Of the eighty 
patients that received adjuvant treatment, twenty-six received palliative 
treatment. Fourteen patients had palliative chemotherapy only without 
radiotherapy and four received palliative radiotherapy only without 
chemotherapy. Eight patients received both. All adjuvant and palliative 
chemotherapy were 5-FU based therapy. Table 22 table 23 shows the 
demographics and treatment response in patients who receive palliative 
chemotherapy only and palliative radiotherapy only.  
 
Table 22: Demographics, Histology and Chemo-response of Patients Undergoing Palliative Chemotherapy Only 
  
  All samples CMS2 CMS3 CMS4 
  Statistics P  Statistics  Statistics Statistics 
Demographics 
and Histology  
n=14  n=9   n=3   n=2   
Gender  0.90          
 M 8 (57.1%)  6 (66.7%)  1 (33.3%)  1 (50.0%)  
  F 6 (42.9%)  3 (33.3%)  2 (66.7%)  1 (50.0%)  
Side  0.40          
Right 4 (8.6%)  2 (22.2%)  1 (33.3%)  1 (50.0%)  
Left 7 (50.0%)   5 (55.6%)  2 (66.7%)  0 (0.0%)  
  Rectum 3 (21%)  2 (22.2%)  0 (0.0%)  1 (50.0%)  
Stage  0.08        
I 2 (14.3%)  0 (0.0%)  2 (66.7%)  0 (0.0%)  
II  2 (14.3%)  1 (11.1%)  1 (33.3%)  0 (0.0%)  
III 5 (35.7%)  4 (44.4%)  0 (0.0%)  1 (50.0%)  




Differentiated 3 (21.4%) 0.41 2 (22.2%)  0 (0.0%)  1 (50.0%)  
Mucinous  1 (7.10%) 0.12 0 (0.0%)  1 (33.3%)  0 (0.0%)  
Lymphovascular 
Involvement  7(50.0%) 0.51 5 (55.6%)  1 (33.3%)  1 (50.0%)  
Extramural 
Venous invasion 6 (35.7%) 0.34 4 (44.4%)  0 (0.0%)  1 (50.0%)  
Extramural 
deposit 2 (14.3%) 0.26 1 (11.1%)  0 (0.0%)  1 (50.0%)  
perineural 
invasion 4 (28.6%) 0.41 3 (33.3%)  0 (0.0%)  1 (50.0%)  
Local Recurrence  2 (14.3%) 0.52 2 (22.2%)  0 (0.0%)  0 (0.0%)  
Subsequent 
Metastasis 
  11 (78.6%) 0.41 7 (77.8%)  3 (100%)  1 (50.0%)  
Chemo-response 
 0.896        
Unknown 1 (7.1%)  1 (11.1%)  0 (0.0%)  0 (0.0%)  
Good 3 (21.4%)  2 (22.2%)  1 (33.3%)  0 (0.0%)  
Poor 9 (64.3%)  5 (55.6%)  2 (66.7%)   2 (100%)  
Nil  1 (7.1%)  1 (11.1%)  0 (0.0%)  0 (0.0%)  
 
 
Of the fourteen patients who underwent palliative chemotherapy only, five 
(35.7%) had stage IV disease at the time of initial surgery and eleven (78.6%) 
developed further distant metastasis. There were no CMS1 tumours within this 
group. There was no significant difference in the demographics, histological 
features and chemo-response between the three subgroups. Two out of the nine 
(22.2%) CMS2 tumours had a good response whereas six out of nine (66.7%) 
either had a poor response or no response at all. One out of the three (33.3%) 
CMS3 tumour had a good response and all two (100%) CMS4 tumour had a poor 
response to palliative chemotherapy.  
 
Table 23: Responsiveness to palliative radiotherapy 
  















radiotherapy Good Good Poor Poor 
 
Of the four patients that solely received palliative radiotherapy only, two showed 
good response to radiotherapy (CMS1 and CMS2) and two showed poor 
response (CMS3 and CMS4).  
 
Table 24: Comparing Rates of Distant Metastasis and Local Recurrence in Patients with Stage II CRCs and Who 
Received Adjuvant Chemotherapy 
 n Subsequent 
Metastasis 
OR P Local Recurrance OR P 
CMS1 2 1 (50.0%) 2 0.65 0 (0.0%) 0.89 0.62 
CMS2 9 3 (33.3%) 1 (11.1%) 
OR – Odds’ Ratio, P – P Value. No CMS3 or CMS4 was included in this table as they did no develop any relapse 
 
Table 25:Comparing Rates of Distant Metastasis and Local Recurrence in Patients with Stage III CRCs and Who 
Received Adjuvant Chemotherapy 
 n Subsequent 
Metastasis 
P Local Recurrance P 
CMS1 9 2 (22.2%) 0.62 0 (0.0%) 0.64 
CMS2 26 7 (26.9%) 2 (7.7%) 
CMS3 9 1 (11.1%) 0 (0.0%) 
CMS4 3 2 (66.7%) 0 (0.0%) 
OR – Odds’ Ratio, P – P Value 
 
Table 24 and Table 25 shows patients who have Stage II and III disease and who 
received adjuvant chemotherapy, there were no significant differences in the 
local recurrence rates or the rates of distant metastasis between the different 









Figure 17:Comparing Disease Free Survival of Stage II CRCS Between Patients Who Received Adjuvant Chemotherapy 






Figure 18: Comparing Disease Free Survival of Stage III CRCS in Patients Who Received Adjuvant Chemotherapy and 
Those That Did Not 
 
When subset analysis on stage II and Stage III patients were performed, no 
significant difference was seen in the five-year DFS between patients who 
received adjuvant chemotherapy versus those who did not (Figure 17 and 18). 
There was a trend towards a lower DFS in patients with stage II disease and those 
who received adjuvant therapy (50% vs 70% for CMS1 and 53.3% VS 78.2% for 
CMS2). In Stage III disease, there was a trend towards a higher DFS for patients 
who received adjuvant therapy in all subtypes except CMS2 (72.7% vs 68.4% for 







To date, no studies have directly evaluated the response of different CMS 
subtypes to adjuvant treatment. This study attempted to do so in two parts. In 
the first part, the aim was to directly assess the response of individual CMS 
tumours towards chemotherapy and radiotherapy. To achieve this, only patients 
who underwent palliative treatment with disease in-situ were included. Analysis 
of patients who had single mode therapy (i.e. those that had only palliative 
chemotherapy or those that only had palliative radiotherapy) was performed to 
accurately distinguish response to chemotherapy or radiotherapy. As for the 
second part, the aim was to assess the response to adjuvant chemotherapy in each 
individual subtype by evaluating their local recurrence rate, rate of distant 
metastasis and DFS. Trying to achieve both parts of the study has led to the 
significant reduction in the number of patients included in the analysis, creating 
the biggest limitation to the current study (twenty-eight patients) and thus 
exposing this study to type II error and making it difficult to draw any 
meaningful conclusion.  
 
It is interesting to see that CMS4 tumours had the poorest response with both the 
CMS4 patients responding poorly to palliative chemotherapy and radiotherapy. 
CMS3 and CMS2 tumours had similar mixed responses. This represents the first 
study to attempt to visualise directly the response in different CMS subtypes to 
palliative treatment. Recruiting larger numbers of patients who received 
palliative chemotherapy would have given a better picture of response, however 
the ability to accurately assess treatment response would still be challenging 
given the recent evidence suggestive of subtype changing that occurs in distant 
metastasis[112]. Trumpi et al suggested that there was at least 50% incongruency 
in the subtyping between primary tumour and the distant metastasis[112]. 
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Unless all distant metastases are biopsied and subtyped in clinical practice, we 
would never be able to address this error accurately. 
 
With regards to response to adjuvant chemotherapy, it is disappointing to see 
that there was no significant difference in the local recurrence rate, rate of distant 
metastases or five-year DFS amongst the CMS subtypes. In all CMS subtypes, a 
trend towards a higher DFS was observed in patients with stage III disease when 
compared to patients with stage II disease. This suggests that the TNM staging 
system remains a far superior tool in determining who receives 5-FU based 
adjuvant chemotherapy. Rodriguez-Salas et al and multiple other studies[88, 127-
129] have shown that 5-FU based adjuvant therapy was only beneficial in Stage 
III disease, and in Stage II disease, 5-FU could have a negative effect on disease 
free survival. 
 
Despite this, CMS subtyping may be useful in determining different antibody-
based therapy. CMS1 tumours are highly immunogenic tumours with increased 
neo-peptide presentation to major histocompatibility complex 1 (MHC-1), 
therefore there is increasing evidence favouring the use of pembroluzimab (PD-
1 inhibitor) in the treatment of CMS1 tumours, particularly those that are 
MSI[116, 119, 132, 133]. In 2015, a phase II trial showed a 40% response rate in 
MSI tumours to pembroluzimab[18].  
 
CMS4 tumours on the other hand are highly enriched in epithelial-mesenchymal 
transition (EMT) associated genes[85, 119]. Multiple studies are currently 
underway to assess the efficacy of monoclonal antibodies against this, 
particularly the TGF-β signalling pathway (NCT02873195, NCT02291289, 
NCT02876224, NCT01633970)[120, 134]. Targeting this pathway will hopefully 
switch CMS4 tumours back to CMS1-like immune-responsiveness and thus 
allowing the introduction of checkpoint inhibitors such as pembroluzimab to 
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improve survival outcomes[88]. Anti-angiogenic drugs such as bevacizumab 
(anti-VEGFR antibody) have also been shown to be effective when used in 
combination with FOLFIRI (folinic acid, 5-FU, irinotecan) or FOLFOXIRI (folinic 
acid, 5-FU, oxaloplatin, irinotecan) in patients who have metastatic CRCs[88, 135, 
136].   
 
CMS2 and CMS3 tumours unfortunately are not immunogenic[85]. These 
tumours either show strong epithelial phenotype or have enrichments in 
metabolic pathways, especially KRAS is CMS3 tumours[85]. Increasing the 
immunogenicity of these tumours by promoting the expression of MHC-I 
through the usage of cobimetinib (a MAPK inhibitor) have been suggested in a 
few studies[120, 137]. This is particularly true of tumours enriched in KRAS 
mutation[137]. A small study of only twenty-two cancers showed that a 
combination of PD-1 inhibitor and cobimetinib resulted in partial response in 
18% of patients[138]. 
 
Despite this, none of these studies were designed using CMS based classification. 
More large-scale studies are required to evaluate chemoresponsiveness of 





In conclusion, this study has not shown significant difference in the response to 
adjuvant treatment among different CMS subtypes. TNM staging system 
remains the classification system of choice in terms of determining adjuvant 
treatment. The future may lie in targeted antibody treatments and large-scale 









Aim: To evaluate the congruity in the Consensus Molecular Subtyping (CMS) of 
primary colorectal cancer (CRC) and hepatic metastasis. 
 
Methods: 10 patients were selected. Frozen tissue of both primary and liver 
metastasis was divided, and RNA extracted. Sample preparation, including 
library creation and ribosomal RNA depletion was carried out using Illumina 
TruSeq V2 reagents (NZGL, Massey University, Palmerston North). RNA 
sequencing was carried out using Illumina HiSeq 2500 V4 platform. Raw 
sequence reads were checked and mapped to a human reference genome. Gene 
Expression profiles from each patient were used as input data to the publicly 
available CRC subtype classifier[85]. The 5-year follow-up data were collected 
retrospectively from patient notes.  
 
Results: Nine out of ten patients had primary tumours that were classifiable. 
Seven were classified as CMS2, one was classified as CMS3 and one as CMS4. 
Four had incongruent classification in subsequent metastasis. Three out of four 
patients with incongruent classification had neoadjuvant chemotherapy prior to 
resection (P=0.02). 
 
Conclusion:  Despite having only ten patients, this study has successfully shown 
incongruency between the CMS Subtyping of primary CRCs and distant 
metastasis in a substantial proportion of patients. More importantly there was a 
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significant association with neoadjuvant therapy. Further investigation in this 





CRCs are complex disease with heterogeneous outcomes. Improvements have 
been made to the molecular classification and adjuvant therapy particularly 
targeted checkpoint inhibitors to improve outcomes. CMS1 and CMS4 tumours 
in particular show distinct prognosis and survival outcomes[85].  Effectiveness 
of treatment depends on the accuracy of classification of CRCs. It is still uncertain 
as to whether the molecular subtyping is preserved when metastasis occurs. A 
recent study has shown incongruency between primary tumour and subsequent 
metastasis[112]. In this chapter, the aim was to perform a pilot study to assess 
this potential and to lay the foundation for larger scale study to evaluate the 
congruency of CMS subtyping in both primary tumour and distant metastasis. 
 
6.3 Methods  
 
Due to funding restrictions, only ten patients were recruited into this study. The 
first ten patients who underwent primary colorectal resection and subsequent 
liver resection and who had both tumours stored in the Cancer Society Tissue 
Bank were identified and selected from the cohort of 306 patients described in 
Chapter 3.  The process of nucleic acid extraction, sequencing and classification 
into the four subtypes of both primary tumour and liver metastasis were carried 
out in a similar fashion to what has been described in Chapter 3. Follow-up data, 
including survival, recurrence and distant metastasis were collected 
retrospectively from patient notes. Data was then entered into a custom-built 
Microsoft Access database (Microsoft, Redmond, Washington, USA). Statistical 
analysis using Fischer’s exact test for categorical data. This was performed using 






Ten patients were identified from the initial cohort of 306 patients. Of the ten 
patients, nine patients had primary CRCs that were classifiable, seven were 
CMS2, one was CMS3 and one was CMS4. There was no CMS1 tumour within 
this cohort. Table 26 shows the clinical characteristics of the nine classifiable 
patients. Four patients had synchronous liver metastasis and five had 
metachronous liver metastasis. Three patients underwent neoadjuvant 
chemotherapy prior to liver resection. 
 
Table 26: Demography and clinical features of patients who had both colonic resection and liver resections 
 












No 2 2 
2 Male Left Colon Metachronous 
liver 
metastasis 
Yes 2 4 
3 Male Left Colon Metachronous 
liver 
metastasis 
No 2 2 
4 Male Left Colon Metachronous 
liver 
metastasis 
No 3 Not 
classifiable 





Yes 2 4 
6 Male Left Colon Metachronous 
liver 
metastasis 
No 2 2 
7 Female Rectum Synchronous 
liver 
metastasis 
Yes 2 4 





No 4 2 










Figure 19: Congruency in CMS classification between primary CRC and liver metastasis 
 
Of the nine patients who had classifiable primary tumour, incongruency 
occurred in five patients (Figure 19). As shown in Table 26, three “switched” from 
CMS2 to CMS4, one “switched” from CMS 3 to unclassifiable and one “switched” 
from CMS4 to CMS2. There was a significant association with neoadjuvant 
therapy. Three out of the five incongruent liver metastasis received neoadjuvant 




This study represents the second only study investigating the congruency of 
Consensus Molecular Subtyping between CRCs and hepatic metastasis. The 
other study published by Trumpi et al[112] utilised immunohistochemistry to 
classify tumours into epithelial-like tumours and mesenchymal-like tumour. This 
is the first study that utilise genome wide analysis to classify CRCs and hepatic 
metastasis into the four CMS Subtype.  
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The biggest flaw with this pilot study is that it only had nine patients, thus 
making it difficult to draw any meaningful conclusions. Despite this, 
incongruency in the molecular subtyping of hepatic metastasis was shown in a 
substantial proportion of the cohort (n=5). More importantly is the strong 
association with neoadjuvant chemotherapy. All three patients who received 
neoadjuvant therapy had incongruency in the molecular classification of liver 
metastasis, whereas four out of six patients who did not receive neoadjuvant 
therapy had congruent molecular classification in the liver metastasis. This 
finding is similar to that of Trumpi et al who suggested that neoadjuvant therapy 
leads to “switching” of subtyping within the liver metastasis[112]. This would 
support the idea of intra-tumoural difference that exists within a tumour 
(Chapter 1). Each tumour is made up of a multitude of sub-clonal cells, each 
having distinct biological and molecular properties with varying degrees of 
mutation[44]. It is hypothesized that selection pressure from neoadjuvant 
chemotherapy leads to a mesenchymal predominant sub-clonal population, 
hence a “switch” in CMS. This is also seen in other epithelial malignancies such 
as breast cancer[46, 139, 140]. Studies have shown that chemotherapy, 
particularly neoadjuvant therapy has led to an incongruency in the molecular 
classification between primary breast cancer and distant metastasis and a change 
in HER-2 status[139-141].   
 
CMS4 tumours have been shown to have a worse survival and prognosis[85]. 
Whether this chemotherapy induced “switch” to CMS4 tumour will lead to a 
worse clinical outcome has yet to be assessed. The benefit resulting from the 
downstaging and improved resectability as a result from neoadjuvant 
chemotherapy must be weighed up against the potential poor prognosis 
associated with CMS4 subtype switching. Further large-scale studies are needed 
to first, validate the subtype incongruency associated with neoadjuvant 
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chemotherapy and secondly, to validate if this switch in subtype is associated 





In conclusion, this pilot study showed potentially the presence of incongruences 
in the Concensus Molecular Subtyping between primary CRCs and hepatic 
metastasis. It raises the possibility that neoadjuvant chemotherapy induces 
switching in these metastases. This needs to be further assessed with large scale 









7. Conclusion Chapter 
 
 
This study utilises RNA-sequencing-derived data extracted from CRCs stored 
within the Cancer Society Tissue Bank (CSTB) to externally validate the 
Consensus Molecular Subtyping (CMS) of colorectal cancer (CRC). We 
successfully externally validate The CMS of colorectal adenocarcinoma (CRC) 
and produced similar clinical-pathological results to Consensus Consortium. 
However, the prognostic and predictive value of this classification system 
remains in doubt.  
 
The aim of Chapter 2 was to analyse the demographics of patients whose CRCs 
were stored within the CSTB and to assess if it was representative of the wider 
overall population. The epidemiology and survival outcomes of the current 
cohort are comparable to published results worldwide[15, 89, 106, 107]. Chapter 
1 also reinforces the notion that no clinical or histological reliable variables other 
than advanced disease and recurrence were predictive of adverse outcomes. This 
highlights the need for a more robust and reproducible classification for 
prognosticating and predicting outcomes for CRCs. 
 
The key findings in Chapter 3 are that firstly, the clinical and histological findings 
of each CMS subtype in this study matches that of the Colorectal Subtyping 
Consortium (CRCSC)[85]. Secondly, and more interestingly is that this study had 
a higher proportion of CMS1, CMS2, unclassifiable tumours and a lower 
proportion of CMS4. There is increasing evidence that disputes the presence of 
CMS4 tumours with suggestion that the presence of EMT-associated genes seen 
in CMS4 tumours may reflect upregulated genes derived from fibroblast and 
mesenchymal cells present in the stromal background rather than directly from 
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the tumour itself[55, 72, 87, 88]. This has direct implications on the prognostic 
accuracy of the CMS classification. More research into this field is required. 
 
Chapter 4 successfully shown distinct survival patterns of each individual CMS 
subtype. However, the difference in survival was seen mainly between CMS4 
and the other subtypes. More importantly, this study showed that the CMS 
classification system did not outperform the traditional TNM staging system in 
terms of prognosticating survival outcomes. This result limits the translation of 
this tool into current clinical practice.  
 
In Chapter 5, due to the small numbers of the cohort, it is difficult to draw any 
meaningful conclusions from this study. No significant trend in response to 
chemotherapy or radiotherapy was identified between the different CMS 
subtypes. Despite this, there was evidence to suggest that the use of 
chemotherapy in stage II disease, leads to a more deleterious result, further 
reinforcing that TNM staging system remains the more robust tool in 
determining the use of adjuvant chemotherapy. The future of the CMS system 
may lie in determining and predicting the use of targeted antibody treatments. 
 
Chapter 6 showed potential incongruences in the CMS between primary CRCs 
and hepatic metastasis and raises the possible association of neoadjuvant 
chemotherapy with the switching in the subtyping of hepatic metastasis. The 
main limitation is that only nine patients were included in this pilot study. The 
implication of this and the application of neoadjuvant therapy particularly in the 
setting of rectal adenocarcinoma needs further investigation. 
 
In summary, when initially published, the CMS Classification showed great 
promise in terms of predicting outcomes. However, findings from this thesis 
have shown that at its present form, the CMS classification does not outperform 
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the traditional TNM staging system in terms of prognosticating survival or 
determining and predicting response to adjuvant chemotherapy. The potential 
absence of CMS4 subtype further dilutes the predictive ability of the CMS 
classification.  This together with potential incongruency of classification in the 
distant metastases, raises the question as to how clinically useful this 
classification system is. With improvements in tumour sampling techniques and 
enhancements in the RNA purification methods, the predictive and prognostic 
ability of the CMS classification system may improve.   The future of 
individualising cancer treatment may well lie in the genetics of colorectal cancer, 
however, as of the current state, the CMS classification is too expensive and not 






Table 27: Kirklin, Dockerty and Waugh modification of Dukes' Classification [12] 
Kirklin, Dockerty and 
Waugh modification 
 
A Carcinoma limited to the mucosa 
B1 Carcinoma that have extended into, but not through the 
muscularis propria 
B2 Carcinoma that have penetrated the muscularis propria 
C metastases are present in the regional lymph nodes 
 
 




A Carcinoma limited to the mucosa 
B1 Lesions extending into the muscularis propria, but not 
penetrating it, with negative nodes 
B2 Lesions penetrating the muscularis propria, with 
negative nodes 
C1 Lesions extending into the muscularis propria, but not 
penetrating it, with positive nodes 




Table 29: Amsterdam II Criteria [68] 
Amsterdam II Criteria 
Three or more relatives with Lynch associated cancer 
Two or more successive generations affected, one is first degree relative of the other 
two 
One or more relatives is diagnosed before age of 50 
Familial polyposis has been ruled out 
 
 
Table 30: Revised Bethesda Guidelines[69] 
Revised Bethesda Guidelines 
CRC diagnosed in patient less than 50 years of age 
Presence of synchronous, metachronous CRCs or HNPCC associated tumours 
CRCs with MSI-H histology diagnosed in patients less than 60 
CRCs diagnosed in one or more first degree relative with an HNPCC related 
tumour, with one cancers being diagnosed less than 60 years of age 
CRCs diagnosed in two or more first or second degree relative with HNPCC related 
tumour, regardless of age 
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Table 31: Demographics and Clinico-pathological Findings of Each CMS Subtypes 
    All samples CMS1 CMS2 CMS3 CMS4 
Clinico-pathological features 
Statistics P value Statistics P value Statistics P value Statistics P value Statistics P value 
      OR   OR   OR   OR 
Age   n=254 <0.01 n=59 <0.01 n=139 <0.01 n=40   16 <0.01 
  Median  73.8   78.17   72.75   74.06   72.85   
  (range)  29-92   31-92   37-90   37-89   52-85   
 Gender   n=254 <0.01 n=59 <0.01 n=139 <0.01 n=40 0.37 n=16 0.77 
  Male 46.4% 118 27.1% (16)   56.1% (78) 1.61 40% (16)   50% (8)   
  Female 53.5% 136 72.9% (43) 2.95 43.9% (61)   60% (24) 1.15 50% (8) 1.17 
 Site   n=254 <0.01 n=59 <0.01 n=139 <0.01 n=40 0.29 n=16 0.05 
  Right colon 43.7% (111)   79.7% (47)  2.42 28.1% (39)  55% (22)   18.8% (3)   
  Left colon 37.4% (95)   18.6% (11)   46.8% (65)  1.92 30% (12)   43.8% (7)  2.42 
  Rectum 18.9% (48)   1.7% (1)   25.2% (35)   15% (6)   37.5% (6)   
 Stage   n=254 <0.01 n=59 0.07 n=139 0.54 n=40 0.06 n=16 0.03 
  I 18.9% (48)   16.9% (10)   17.3% (24)   30% (12)   12.5% (2)   
  II 42.9% (109)   55.9% (33)   44.6% (62)   27.5% (11)   18.8% (3)   
  III 31.9.3% (81)   25.4% (15)   30.2% (42)   40% (16)   50% (8)   
  IV 6.3% (16)   1.7% (1)   7.9% (11)   2.5% (1)   18.8% (3)   
T Staging   n=254 0.04 n=59 0.51 n=139 0.06 n=40 <0.01 n=16 0.86 
  1 3.1% (8)   3.4% (2)   0.7% (1)   12.5% (5)   0% (0)   
  2 19.7% (50)   15.3% (9)   21.6% (30)   20% (8)   18.8% (3)   
  3 62.2% (158)   61% (36)   64.7% (90)   52.5% (21)   68.8%(11)   
  4 15% (38)   20.3% (12)   12.8% (18)   15% (6)   12.5% (2)   
N Staging   n=254 0.02 n=59 0.03 n=139 0.92 n=40 0.55 n=16 <0.01 
  0 62.6% (159)   76.3% (45)  1.75 61.9% (86)   57.5% (23)   31.2% (5)   
  1 25.6% (65)   18.6% (11)   26.6% (65)   32.5% (13)   25% (4)   
  2 11.8% (30)   5.1% (3)   11.5% (30)   10% (4)   43.8% (7)   
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M staging   n=254 0.04 n=59 0.10 n=139 0.24 n=40 n=0.28 n=16 0.03 
  0 93.7% (238)   98.3% (58)   92.1% (128)   97.5% (39)   81.2% (13)   
  1 6.3% (16)   1.7% (1) 0.93 7.9% (11) 1.03 2.5% (1) 2.8 18.8% (3) 3.44 
Poorly 
differentiated  
  n=254 <0.01 n=59 <0.01 n=139 <0.01 n=40 0.24 n=16 0.48 
  No 80.7% (205)   50.8% (30)   90.6% (126) 1.39 87.5% (35)   87.5% (14)   
  Yes 19.3% (49)   49.2% (29) 4.78 9.4% (13)   12.5% (5) 0.91 12.5% (2) 1.58 
Mucinous   n=254 <0.01 n=59 <0.01 n=139 <0.01 n=40 0.07 n=16 0.71 
  No 92% (229)   79.7% (47)   97.1% (135) 6.34 82.5% (33) 1.11 87.5% (14) 1.33 
  Yes 9.8% (25)   20.3% (12) 3.57 2.9% (4)   17.5% (7)   12.5% (2)   
signet ring   n=254 0.34 n=59 0.37 n=139 0.12 n=40 0.18 n=16 0.71 
  No 99.2% (252)   98.3% (58) 1.01 100% (139) 0.98 97.5% (39) 1.02 100% (16) 0.99 
  yes 0.8% (2)   1.7% (1)   0%   2.5% (1)   0%   
Lymphovascular 
invasion 
  n=254 0.97 n=59 0.91 n=139 0.66 n=40 0.70 n=16 0.91 
  No 70.1% (178)   69.5% (41) 1.01 71.2% (99) 0.96 67.5% (27) 1.04 68.8% (11) 1.02 
  Yes 29.9% (76)   30.5% (18)   28.8% (40)   32.5% (13)   32.7% (5)   
perineural 
invasion   n=254 0.59 n=59 0.54 n=139 0.62 n=40 0.48 n=16 0.28 
  No 89.4% (227)   91.5% (54) 0.96 88.5% (123) 1.02 92.5% (37) 0.96 81.2% (13) 1.11 
  Yes 10.6% (27)   8.5% (5)   11.5% (16)   7.5% (3)   18.8% (3)   
isolated 
extramural deposit 
  n=254 0.03 n=59 0.74 n=139 0.50 n=40 0.19 n=16 <0.01 
  No 92.5% (235)   91.5% (54) 1.01 93.5% (130) 0.97 97.5% (39) 0.94 75% (12)   
  Yes 7.5% (19)   8.5% (5)   6.5% (9)   2.5%(1)   25% (4) 3.97 
extravenous 
invasion   n=254 0.35 n=59 0.70 n=139 0.61 n=40 0.23 n=16 0.16 
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  No 86.6% (220)   88.1% (52) 0.98 85.6% (119) 1.02 92.5% (37) 0.92 75% (12) 1.17 
  
Yes 13.4% (34)   11.9% (7)   14.4% (20)   7.5% (3)   25% (4)   
Adjuvant 
chemotherapy   n=254 0.01 n=59 0.03 n=139 0.17 n=40 0.94 n=16 0.47 
  no 67% (205)   81% (48)   66.9% (93)   70% (28)   62.5% (10)   
  yes 33% (101)   18.6% (11) 1.76 33.1% (46)   30% (12)   37.5% (6)   
MSI   n=32 <0.01 n=10 <0.01 n=12 <0.01 n=9 0.76 n=1 0.43 
  
No 62.5% (20)   10% (1)   100% 0.4 66.7% (6) 0.77 100% 0.95 
  Yes 37.5% (12)   90% (9) 57 0%   33.3% (3)   0%   
            
Local Recurrance  n=254 0.55 n=59  n=139  n=40  n=16  
  10 (3.9%)  3.9%  (2)  3.6% (5)  7% (3)  0% (0)  
Subsequent distant 
metastasis  n=254 0.19 n=59  n=139  n=40  n=16  
  45 (17.7%)  11.9% (7)  20.1% (28)  12.5% (5)  31.2% (5)  
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